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Chair: Anna K. Mapp 
Critical to the regulation of nearly every cellular process are protein-protein 
interaction (PPI) networks whose constituent contacts differ dramatically in 
affinities, lifetimes, and interaction interface area. For example, PPIs are 
essential to transcriptional regulation, a process in which transcriptional 
activators dynamically engage in a diverse series of binding interactions to recruit 
numerous multi-protein coactivator complexes to the promoter of a gene to be 
transcribed.  Activators make specific, high affinity contacts with masking 
proteins but they also engage in weaker affinity, more transient interactions with 
the transcriptional machinery. These weaker affinity, transient PPIs are important 
as they are believed to play a significant role in modulating the function, 
localization, and specificity of key complexes that are central to PPI networks. 
Given the fundamental role that PPIs play in executing cellular processes such 
as transcription initiation, a longstanding goal has been to design small 
molecules that will transiently modulate these contacts and reveal key insights 
into how they function in the context of their associated networks.  However, this 
goal has proven to be quite challenging as currently just a small fraction of PPIs 
are targeted with small molecules. Of the thousands of contacts that remain, 
many are considered impossible to target, particularly those that are more 
transient in nature.  In many cases, characterizing these PPIs using commonly 
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employed affinity based methods is challenging.   Thus, methods capable of 
capturing a broad spectrum of PPIs, particularly in their native cellular 
environment, should prove incredibly useful. 
 
The major goal of this thesis is to demonstrate the utility of in vivo 
photocrosslinking with a genetically incorporated photo-labile amino acid p-
benzoyl-L-phenylalanine (Bpa) in capturing the direct targets of transcriptional 
activators in living cells.  Using this methodology, the interaction with the 
Mediator protein Med15 was captured, indicating the power of this approach in 
capturing weaker affinity interactions that have historically been challenging to 
study.  Furthermore, the direct targets within the Swi/Snf chromatin remodeling 
complex were identified, indicating the compatibility of this approach in studying 
transcriptional systems that often utilize low-abundance complexes.  In 
combination with formaldehyde crosslinking, in vivo crosslinking with Bpa 
demonstrates for the first time the ability to capture the direct targets of DNA 
bound activators.  And finally, using mass spectrometry to identify binding 
partners of transcriptional activators reveals several novel targets, thus 









1.A. Overview of protein-protein interaction networks 
Protein-protein interactions (PPIs) form the backbone of nearly every facet of 
cellular function. Remarkably complex, PPI networks are composed of thousands 
of contacts that range from very stable and high affinity to interactions that are 
much weaker and more transient in nature.  Exemplifying complex PPI profiles 
are transcriptional activators, a family of signal responsive proteins that localize 
to gene promoters and recruit the necessary transcriptional complexes required 
to upregulate gene expression.  In the cell, activators are believed to dynamically 
interact with numerous protein complexes, and the contacts include high-affinity 
interactions with masking proteins in addition to weaker, transient interactions 
with transcriptional coactivator complexes.  As with other functionally important 
transient PPIs, visualization of direct activator-coactivator interactions has proven 
challenging given the dynamics of the association and structural plasticity of the 
interaction interfaces.  As a result, much remains unclear regarding the 
mechanism by which activators recruit coactivator complexes in vivo in order to 
upregulate transcription. Thus, a longstanding goal has been develop probes and 
tools that can be used to define these interactions in a cellular setting. 
Although the goal of modulating PPIs has been recognized for some time, 
these interactions have been historically challenging to target with small 
molecules.2-4  Indeed, the majority of PPIs have been broadly classified as 
“undruggable” and among the estimated 650,000 PPIs in the cell, far less than 
                                                          
1
 Portions of this Chapter are from from published work regarding the challenges associated with targeting 
protein-protein interactions:  (1) Thompson, A. D.; Dugan, A.; Gestwicki, J. E.; Mapp, A. K. ACS Chem. 
Biol. 2012, 7, 1311. 
2 
 
0.01% have been targeted with inhibitors.2,4-6  Upon closer examination of the 
PPIs utilized in transcriptional systems, a sharp decline is observed in the 
amount of high-resolution structural and mechanistic data required for the 
rational design of small molecule modulators intended to perturb these 
interactions.  This lack of information can be attributed in part to the limitations of 
the methods currently available for studying the broad spectrum of PPIs that exist 
and the even smaller number of methods able to examine PPIs in their native 
cellular environment.7-9  As such, new methodologies with this application in mind 
are essential to advancing progress toward creating complete functional maps of 
transcription PPI networks.   
1.A.1. Diversity of PPIs and associated challenges in targeting with small 
molecules 
PPIs differ greatly in binding affinity and contact area, making a one-size-fits-all 
approach in targeting them difficult to achieve. In contrast to protein-ligand 
interfaces (PLIs) such as those between an enzyme and its substrate, PPIs tend 
to be larger and flatter, with an average surface area of 1940 +/- 760 Å2.3,10,11  
Consistent with their wide distribution of contact areas, PPIs exhibit a wide range 
of affinity values, with examples of pM dissociation constants in more stable 
complexes and mM values in transient complexes.8,12,13  Several examples of 
PPIs with a diverse range of affinities and contact areas are highlighted in Figure 
1-1 and Table 1-1.14-18  The scope of this diversity is postulated to be even 
greater than currently appreciated given the underrepresentation in the Protein 
Data Bank (PDB) of transient, low affinity and membrane associated PPIs.8,19  
Structure-based drug design approaches have been particularly successful in 
targeting tight affinity and small surface area PPIs (e.g. most similar to PLIs) as 
they have been more amenable to characterization using standard structural and 
biochemical approaches.  In fact, a 2012 query of the 2P2IDB and TIMBAL 
databases, which analyze PPI interfaces and the small molecules available to 
target PPIs, respectively, revealed an overwhelming number of PPI inhibitors for 
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contacts with smaller surface areas (less than 1,800 Å2) and relatively tight 
affinities (nM dissociation constants).  In fact, this class of PPIs was found to be 
targeted by approximately 68% of reported small molecules.1,20,21  In contrast, 
only about 10% of known inhibitors target PPIs that are of moderate to weak 
affinity (≥1 M).  We expect that this disparity in targeting ability will diminish with 
the advancement of methods better-suited to study this challenging class of PPIs, 
thus revealing features necessary to guide drug discovery efforts. 
 
 
 Figure 1-1  (Top) PPIs from a variety of interaction networks cover a broad spectrum of affinities 
and contact areas.  Analysis of PPIs using these two variables leads to four major quadrants to describe 
these interactions: strong and concise (grey, upper left), strong and broad (blue, upper right), weak and 
concise (green, lower left), and weak and broad (pink, lower right).  Examples of each type of interaction 
from the Protein Data Bank (PDB) are shown.  Strong and concise: p53-MDM2 (1YCQ), Bcl-xL-BAX (2XA0), 
XIAP-SMAC (2JK7, 1G73); strong and broad: IL-2-IL2R (2ERJ), Ran-RanBP2 (1RRP), Cul1-CAND1 (1U6G); 
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weak and concise: CBP KIX-cMyb complex (1SB0), MCP-1 dimer (1DOM), and Ras-p120GAP (1WQ1); 
weak and broad: cadherin-8-homodimer (1ZXK) and p53-CBP NRID (2L14).  (Bottom) PPIs with known 
inhibitors were gathered from the 2P2IDB and TIMBAL databases and categorized based on the PPI binding 
affinities (as reported in the PDBbind) and the surface area of the interaction (as measured by InterProSurf.)  
Analysis revealed that an overwhelming majority of known PPI inhibitors target PPIs with smaller surface 
areas (<1800 Å
2
) and relatively tight affinities (<1 mM).  Colors on graph correspond to the quadrant they 
target.  Table with values corresponding to PPI placement in Figure 1-1 is shown below. Analysis performed 















 0.42 650.6 
BcL-XL-BAX
24
 0.015 502-828.6 
IL2R-IL2
25








 0.001 4928.6 
MCP-1 dimer 0.5 1720 
CBP KIX-cMyb
28
 15 1320 
Ras-p120GAP
29








 80 2663.1 
 
Table 1-1 – Associated values for Figure 1-1.  Binding affinities and interface areas for PPIs within each 
category in Figure 1-1 are listed.  Interface surface areas were calculated using 2P2IDB database for the 
PDB IDs listed in Figure 1-1 and binding affinities were pulled from the literature.  
1.B. Transcriptional activator PPIs: a case study in the difficulties in studying and 
targeting transient interactions. 
Transient and weaker affinity contacts are of particular interest in biological 
systems as they enable individual proteins to serve multiple functions, often by 
re-using the same interfaces.  This strategy is heavily featured in transcriptional 
up-regulation, a process in which transcriptional activators engage in a multitude 
of interactions using a single transcriptional activation domain (TAD) to assemble 
the transcriptional machinery at the promoter of a gene.  This assembly requires 
a series of dynamic binding interactions between the TAD and a variety of 
coactivator complexes, including chromatin-modifying enzymes, helicases, and 




Figure 1-2 The transcriptional activation domain (TAD) of amphipathic activators can engage in high-affinity 
interactions, such as those with masking proteins (mp), but the interactions between the TAD and 
coactivator complexes are more moderate in affinity and transient in nature. 
 
Activators can additionally make high affinity (low nM) contacts with masking 
proteins that repress their activity.  These activator-masking protein interactions 
fall solidly in the area of Figure 1-1 that has proven to be the most amenable to 
targeting with small molecules.  Indeed, a crystal structure of the activator p53 
bound to its masking protein MDM2 shows an interaction more reminiscent of a 
PLI, with a concise alpha-helix of the p53 TAD binding tightly to a well-defined 
cleft on MDM2.33  Not surprisingly, the p53-Mdm2 interaction is one of the most 
successfully targeted by small molecules due to its well-defined binding pocket, 
the structure of which was solved thanks to an advantageous compatibility of this 
class of PPIs with crystallization conditions.34  Whereas interactions with masking 
proteins can be specific and high affinity, activator-coactivator interactions are 
often mediated through lower affinity, transient contacts.32,35-39 As shown in 
Figure 1-3, the PPIs that p53 maintains with coactivators during recruitment are 
far more diverse in contact area (~800-2500 Å2) and exhibit dissociation 
constants that fall in the high nM to low mM range.33,40-42 Thus, the interactions 
most critical to understanding how p53 upregulates gene expression belong to 





Figure 1-3   The field of transcriptional regulation is a prime example of a single system that engages in a 
diverse range of interactions.   The transcriptional activator and tumor suppressor p53 engages in 
interactions that include the four major types of PPIs.  The interaction between p53 and its repressor protein 




 whereas the p53 




 also maintains a high affinity interaction but with a broader 
PPI interface.  The interactions of p53 with the transcriptional machinery and coactivators such as the Taz2 
domain of p300 (17 mM) 
40
 are often lower in affinity and range in interaction area (PDB:1 2GS0, 795 Å
2 
to 
PDB: 2L14, 2288.6 Å
2
).  Thus, studying the interactions of a single system can pose significant challenges if 
the methods used are not suitable for covering this wide range of PPIs 
1.B.1. Multi-protein complexes in transcriptional PPI networks 
Further utilization of weaker affinity, transient PPIs in transcriptional systems can 
be seen in the coactivator complexes themselves, which are typically composed 
of at least one enzyme, such as an ATPase, and a series of non-enzymatic 
factors, such as scaffolding and regulatory proteins, that can associate either 
stably or transiently with the complex and help fine-tune activity, subcellular 
location, and/or selectivity.  For example, the combinatorial assembly of BAF-
type chromatin remodeling complexes involved in transcriptional regulation 
permits subunit exchange during the transition from a pluripotent stem cell into a 
neuron progenitor cell and finally into a fully differentiated neuron (Figure 
1-4).45,46  In mouse embryonic stem cells, an esBAF complex containing the 
BRG1 ATPase (but not BRM) and two copies of BAF 155 (but not BAF 170) is 
responsible for regulating transcriptional networks controlling pluripotency in ES 
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cells.47,48  Interestingly, complexes containing BAF 155 and not BAF170 have yet 
to be identified in other cell types, suggesting the importance of this subunit 
specifically in regulating pluripotency.49  Further use of subunit exchange and 
combinatorial assembly is seen in the formation of complex isoforms specific to 
the cell types in which they exist, including npBAF in neuron progenitor cells and 
nBAF in neuronal cells (Figure 1-4).  These isoforms are believed to differentially 
interact with cellular complexes known to be critical to cellular differentiation and 
dendrite formation.49  Thus, subunit exchange of multi-protein complexes 
regulates critical stages of cellular development.  As another example, the Snf1 
kinase/AMPK complex exchanges a regulatory subunit to dictate subcellular 
localization of the complex. In this case, the Gal83 complex isoform is believed to 
play the most significant role in regulating transcription of galactose inducible 
genes, whereas the Sip2 and Sip1 isoforms are believed to play important roles 
in the cytoplasm and vacuole, respectively.    Thus, transient interactions play a 
central role in regulating transcriptional PPI networks.  Further, in the case of 
multi-protein complexes, using small molecules to target the assembly and/or 
disassembly of the constituent contacts has the potential to uncover important 




Figure 1-4 (Top) At the core of transcriptional PPI networks are multi-protein complexes that are often 
composed of at least one enzyme component (red) and several scaffolding and regulatory proteins that can 
associate either stably or transiently with the core subunit.  In many cases, exchange of the non-enzymatic 
subunits can fine-tune complex localization and activity.  (middle) As an example, the BAF-type remodeling 
complex uses subunit exchange to modulate the progression from an embryonic stem cell to a fully 
differentiated neuron.
49
  (bottom) Subunit exchange dictates the subcellularl localization of the Snf1/AMPK 
complex.  
Traditional routes for molecular probe discovery have developed compounds that 
inhibit the enzyme components of multi-protein complexes; however, in 
dynamically exchanging systems, targeting only the enzyme component may not 
be the most informative approach.4  Rather, inhibiting or even promoting specific 
PPIs could be of even greater value for understanding transcriptional regulation 
and a wide range of essential cellular processes, a prospect that is supported by 
a growing appreciation of the potential of PPIs as drug targets.50-53  However, 
achieving this goal has been fraught with difficulty, in part due to the challenges 
associated with characterizing transient, moderate affinity PPIs. The direct result 
of these difficulties is a shortage of the information necessary to guide molecular 
probe design.7,54,55  
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1.C. Challenges in studying activator-coactivator PPIs 
To date, advances in understanding the underlying mechanism of activated 
transcription have largely been from studies that have focused on amphipathic 
activators, the largest and most well-characterized class in eukaryotes.56 This 
family of activators includes the aforementioned p53 as well as such classic 
model systems as the viral activator VP16 and the yeast activators Gcn4 and 
Gal4. One key feature of amphipathic activators is their ability to activate 
transcription across eukaryotes, regardless of their species of origin within this 
domain of life.57-60  As such, when fused to an appropriate DNA binding domain, 
the TADs of mammalian activators such as p53 are able to upregulate 
expression of protein encoding genes in S. cerevisiae.61-63  This not only implies 
a high conservation of the fundamental components of this process across 
kingdoms, but it also suggests that studies of activators in less complex model 
organisms, such as yeast, can be used to form hypotheses about the mechanism 
of activated transcription in more complex systems. For this reason, S. cerevisiae 
has long been a critically important model organism for defining the mechanism 
of eukaryotic gene transcription. 
1.C.1. Structure of activator PPIs 
Amphipathic activators are so named due to the amino acid composition of their 
transcriptional activation domain (TAD), which is used to maintain contacts with 
inhibitory masking proteins, transcriptional complexes, and other contacts outside 
of the transcriptional machinery.  The primary structure of amphipathic TADs is 
generally defined by stretches of acidic and polar residues interspersed with 
hydrophobic amino acids that are believed to play a substantial role in activator 
binding and function.32,64-67  Like other intrinsically disordered proteins, the 
secondary structure of TADs is ill-defined in the absence of a binding partner, 
although it has been suggested that certain regions of the VP16 TAD adopt a 
partial -helical conformation in solution.68  Upon binding to a protein partner, 
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TADs have been shown to fold into an -helix, with the hydrophobic face of the 
helix reported to contain many hotspots involved in maintaining binding 
interactions.68-71 For example, the crystal structures of p53-MDM2 and Gal4-
Gal80 beautifully complement biochemical data supporting the importance of 
hydrophobic residues in activator binding and function, with each structure 
showing hotspot residues in each TAD buried deep within the hydrophobic 
binding cleft on their respective masking proteins (Figure 1-5).42,72,73   In fact, 
small molecules that inhibit the p53-Mdm2 interaction do so by mimicking just 
three hotspot amino acids in the p53 TAD (Phe19, Trp23, and Leu26) that 










Figure 1-5 Activator-masking protein interactions are often defined by high affinity and small interaction 
areas.  Both the p53-Mdm2(blue/yellow) and Gal4-Gal80 (cyan/magenta) interaction entail a small helix of 
the TAD of each activator binding a well defined groove on their respective masking proteins.  The side 
chains of hydrophobic residues in each amphipathic TAD are shown as these are often considered to play a 
substantial role in these binding interactions.  For example, Phe19, Trp23, and Leu26 in the p53 TAD are 
considered hotspots as they contributed the majority of binding energy in the p53-Mdm2 interaction. 
 
In contrast, limited structural data is available for activator-coactivator 
interactions because transient, moderate-affinity PPIs are often not amenable to 
crystallization by standard techniques. As with most intrinsically disordered 
proteins, NMR spectroscopy has been the preferred method for examining the 
structure of unbound activators and weaker affinity activator-coactivator 
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interactions.  Of the few high-resolution structures that do exist for activator-
coactivator PPIs, most are limited to truncated segments of the TAD; thus, a 
complete picture of these binding events has proven difficult to obtain.  Toward 
this goal, a recent approach by the Fersht group using residual dipolar coupling 
NMR combined with small angle X-ray scattering (SAXS) and molecular 
dynamics modeling was used to solve the structure of a modified p53 tetramer 
bound to the TAZ2 domain of p300.75 The production of high-resolution 
structures of activator PPIs may be an increasingly realistic goal as more 
sensitive methods are developed and refined. However, as discussed in the next 
section, structural characterization of activator PPIs is contingent on the 
identification of the direct cellular targets of transcriptional activators, a significant 
roadblock that has hindered efforts toward this goal. 
1.C.2 The elusive targets of amphipathic activators  
The identification of the direct, cellular targets of amphipathic activators has 
proven to be very challenging. The absence of well-defined activator interaction 
profiles has stymied the discovery of small molecules that can modulate or mimic 
these PPIs.32,76  For example, the few compounds capable of mimicking activator 
function were designed to contain hydrophobic and polar substituents as a 
means to simulate the amphipathic nature of activators.77-79  However, these 
molecules only modestly upregulate gene expression and thus require significant 
optimization in order to achieve activation levels on par with natural activators.  
Toward this goal, elucidating the identities of activator targets in vivo and the 
subsequent characterization of these interactions should reveal key mechanistic 
information that can be used to tailor the activity of small molecules that can 
mimic or modulate activator function in vivo.  Critical to this objective are 
methods capable of capturing the wide range of PPIs that activators maintain, 
especially the more transient interactions that have proven most challenging to 
study.  Furthermore, because many of these PPIs occur in the context of multi-
protein complexes that often employ dynamically exchanging subunits, it is 
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particularly useful to have a method that can capture these interactions in their 
native cellular environment. 
 1.C.2.a ChIP and genetic approaches to examine activator PPIs 
Chromatin immunoprecipitation (ChIP) methods have been critical in establishing 
the fundamental role of activators in recruiting coactivator complexes and 
assembling the pre-initiation complex (PIC), which includes RNA polymerase II 
as well as other essential transcription factors. This approach uses formaldehyde 
to rapidly and non-specifically crosslink protein-DNA and protein-protein 
interactions in cells or on DNA templates, immobilizing the complexes that 
activators recruit to a particular promoter in order to regulate gene expression.80 
Thus, the advantage of ChIP is that it allows for the examination of activator 
recruitment on DNA, providing the most relevant information regarding initiation 
events in cells.  Genetic studies have also contributed to this effort by introducing 
point mutations or deleting full proteins or protein domains and examining its 
effect on cell phenotype, complex recruitment, and functional output.81-83 ChIP 
studies have helped lay the groundwork in identifying the proteins and complexes 
involved in transcriptional PPI networks. However, the nature of ChIP 
experiments does not allow one to easily distinguish a direct versus an indirect 
interaction between two proteins.  Thus, the subunits within these recruited 
complexes that serve as activator targets in vivo, in addition to the location of 
activator binding sites within these targets, remain unclear via this route. 
Furthermore, genetic studies can be difficult to interpret owing to pleiotropic 
effects that result from deleting proteins that are critical to a number of PPI 
networks.84  As such, a single deletion has the potential to affect more than just 
the transcriptional system under investigation.  In addition, deletion of a protein 
required for the structural integrity of a complex can cause dissociation of the 
constituent subunits. For example, Gal4 has been shown to recruit the SAGA 
chromatin-modifying complex to the Gal1 promoter and genetic experiments 
were performed to determine which SAGA subunits participate in this recruitment.  
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While deletion of Spt8 resulted in a significant loss of SAGA recruitment by Gal4, 
the same result was achieved upon deletion of Spt7, Spt20 and Ada1, three 
subunits shown to be important for structural integrity of the complex.85. Thus, 
these approaches have left a significant knowledge gap regarding the specific 
coactivator targets of activators in cells.  
1.C.2.b Biochemical approaches to identify activator-coactivator PPIs 
Based on the results of genetic and ChIP studies, it is expected that activators 
target multiple protein partners throughout the course of transcription initiation. 
Indeed, biochemical approaches such as GST-pulldowns and in vitro crosslinking 
have highlighted the binding promiscuity of amphipathic activators, as 
demonstrated in Table 1-2 by their association with multiple targets.  In fact, 
these analyses have generated over fifteen putative targets for VP16 (Table 1-2).  
In vitro binding studies have also identified interactions with little to no cellular 
relevance, including a reported interaction between Gal4 and bacterial lysozyme 
as well as binding of VP16 to Gal80. 86,87  This comes as a result of examining 
activator binding in the context of purified complexes or individual purified 
subunits, conditions that hardly resemble the complex and dynamic environment 
of the cell.88  Providing additional support for studying activator PPIs in cells are 
studies that examined the recruitment of the Mediator complex by Gal4, leading 
to the identification of the Med15 subunit as a target of this activator during 
complex assembly at the promoter.  Early characterization of the interaction 
between Gal4 and Med15 was carried out with purified components in solution.  
However, a recent examination of a ternary DNA-Gal4-Med15 complex suggests 
that the affinity of this interaction is enhanced by the presence of DNA, a finding 
that highlights the importance of examining activator-coactivator interactions in a 
cellular, DNA bound context.35,89  Moreover, experiments with different classes of 
activators have shown that changing the location of DNA binding sites relative to 
the transcription start site can have vastly different outcomes on the 
transcriptional activity of the activator.90  As such, in vitro experiments are likely 
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to overlook variables that may play a critical role in transcription in vivo, thus 
providing an incomplete or inaccurate representation of cellular events.  Finally, 
many in vitro approaches, including GST-pulldowns and co-immunoprecipitations, 
rely on an affinity-based capture of activator PPIs and are therefore not ideally 
suited for the study of more transient, moderate affinity activator PPIs.  
Additionally, further analysis of these putative interactions reveals that activators 
can bind multiple sites within a single coactivator subunit. For example, p53 has 
been found to bind at least four different domains on the coactivator p300.91  
However, identifying which of these sites are functionally relevent in a cellular 
context has been difficult to establish.  
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Table 1-2 A variety of methods have been used to identify putative binding partners of transcriptional 
activators.  This list is not meant to be inclusive, but rather highlight the promiscuous binding profile of 
transcriptional activators, particularly in an in vitro context. 
C.2.c Investigating activator-coactivator interactions in vivo 
In vivo approaches designed to address the limitations of the aforementioned in 
vitro methods have been used to identify the putative binding partners of 
activators in their native cellular environment.  For example, yeast two hybrid 
(Y2H) studies have been heavily employed to look at PPIs in cells.  This method 
is particularly advantageous for activators as it is sensitive enough to detect 
weakly interacting proteins; however, this sensitivity is also its downfall as Y2H 
screens are notoriously susceptible to high rates of false positives.110  Another 
sensitive method, in vivo Forster Resonance Energy Transfer (FRET), has 
produced some convincing results regarding the interactions between Gal4 and 
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individual subunits of the SAGA chromatin modifying complex in yeast.  Gal4 was 
tagged with a cyan fluorescent protein (CFP) and then tested for binding to 
enhanced yellow fluorescent protein (eYFP) tagged SAGA subunits.  In the 
context of these studies, binding is implied upon enhancement of FRET as it 
indicates the two proteins under investigation are in close proximity (less than 50 
Å).  Of the coactivator subunits examined, only Tra1 showed FRET with Gal4, 
suggesting that this component was particularly critical for recruitment of 
SAGA.111  While an important study, the absence of FRET for the remaining 
SAGA subunits (as well as several non-SAGA proteins identified in vitro to be 
Gal4 targets, including TBP) is difficult to interpret as a real result, especially 
given the sensitivity of FRET experiments to proper positioning of the 
fluorophores in use.112  Furthermore, for proteins that primarily exist in the 
context of multi-protein complexes, the fluorophore can often be obscured or may 
disrupt subunit interactions within the complex.    
C.2.d Use of crosslinking reagents to capture activator-coactivator PPIs 
Perhaps the most convincing data in the identification of the direct interactions of 
transcriptional activators comes from studies using crosslinking moieties which 
capture and stabilize transient PPIs, affording the ability to study them under 
conditions that would otherwise prove disruptive. To date, numerous crosslinking 
reagents have been introduced to stabilize activator-coactivator interactions.  
Early experiments with chemical crosslinkers generally focused on incorporating 
the crosslinking moiety in a purified activator and analyzing the crosslinked 
products formed when introduced to either purified complexes or in whole cell 
lysates.38,92,97,100  For example, in a series of elegant studies, the Hahn group has 
demonstrated the utility of crosslinking in capturing activator PPIs in vitro by 
using a PEAS crosslinker to capture the direct targets of Gal4 and Gcn4 in yeast 
cell lysate and later using a genetically incorporated photocrosslinking amino 
acid, p-benzoyl-L-phenylalanine (Bpa) to capture the interactions of TATA 
binding protein (TBP) both in vivo and in live yeast.38,113  Their studies in yeast 
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demonstrated that TBP directly contacts the chromatin modifying SAGA complex, 
allowing them to map the molecular positions of protein components within the 
pre-initiation complex (PIC) in yeast.   
The added advantage of using genetically incorporated photocrosslinking amino 
acids such as Bpa is that they can be site-specifically incorporated within a 
protein domain in cells, thus removing the requirement of introducing the 
crosslinking moiety post-translationally on a purified protein, such as that 
required when using popular PEAS, Sulfo-SBED and many NHS-ester 
crosslinking reagents.  Site specific incorporation is achieved through the use of 
an evolved Bpa-specific tRNA synthetase (BpaRS) that selectively charges a 
tRNA variant whose anti-codon loop matches that of an amber stop codon (UAG) 
in the mRNA being translated.114  Thus, mutation of specific codons in a gene of 
interest to an amber stop codon allows for Bpa to be site-selectively incorporated 
in the protein of interest in vivo.  Furthermore, the tRNABpa and BpaRS react 
bio-orthogonally; the BpaRS does not acylate natural tRNAs with Bpa and the 
tRNA Bpa cannot be charged with natural amino acids by either endogenous 
synthetases or the BpaRS. The Schultz group first developed the use of 
nonsense suppression to incorporate unnatural amino acids such as Bpa into 
proteins in bacterial cells.  Since their initial studies in E. coli, Bpa has 
subsequently been introduced in a similar fashion in eukaryotes including yeast 
and mammalian cells, allowing for the covalent capture of PPIs in the respective 
cell types.115-118  Additional photo-crosslinking moieties have also been 
introduced into proteins via nonsense suppression including p-
azidophenylalanine (pAzpa) and aliphatic diazirine-containing amino acids, thus 
providing several options with which to carry out in vivo photocrosslinking studies.  
While this technology can be used to validate the many putative partners that 
have already been identified, a more powerful application of this methodology 
comes with the use of mass spectrometry to identify novel activator interactions 
in a high-throughput manner.  Finally, because activators can bind coactivators 
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both on and off DNA, the development of a method that allows for the capture of 
DNA bound activator interactions will be of great use in the mapping the contacts 
required specifically at the promoter of genes.  
1.D. Overview of Thesis 
 In the remaining chapters of this thesis, I demonstrate the utility of Bpa 
crosslinking in live yeast in capturing the direct binding partners of transcriptional 
activators whose PPIs vary greatly in affinity, interaction area, and lifetimes.   In 
Chapter 2, we show that Bpa crosslinking in yeast is capable of capturing 
moderate affinity activator interactions, specifically that between VP16 and the 
Mediator subunit Med15.  We additionally demonstrate the capture of low 
abundance, endogenous targets by capturing the interactions between Gal4 and 
VP16 and components of the Swi/Snf chromatin-remodeling complex. Chapter 3 
demonstrates the power of a novel method, Tandem Reversible and Irreversible 
Crosslinking (TRIC), in capturing the direct targets of DNA-bound activators, a 
goal that has not been accomplished until the creation of this approach.  In 
Chapter 4, we use mass spectrometry to identify novel targets of the 
transcriptional activator Gal4, thus bringing us one step closer to a complete 
interaction profile for transcriptional activators.  And finally, in Chapter 5, we 
discuss the future applications of these approaches in guiding small molecule 
discovery and the use of nonsense suppression to incorporate new chemistries 
into transcriptional activators, with the intent of yielding key insights into the 
mechanisms surround coactivator recruitment.     
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Chapter 2 In vivo photocrosslinking captures transient, moderate affinity 
activator-coactivator interactions in living cells  
2.A. Summary2  
Transient and moderate affinity protein-protein interactions (PPIs) play a critical 
role in the regulation of essential cellular processes including protein folding, 
ubiquitylation, and transcription.  A number of disease states are believed to be 
the result of aberrations within these protein networks. Therefore, a longstanding 
therapeutic goal has been to design small molecules that can tunably modulate 
the constituent interactions.3-11  However, as discussed in Chapter 1, the 
discovery of small molecule modulators has been hindered by a lack of structural 
and mechanistic information due to limitations of the approaches currently 
available for studying transient PPIs in their native environment.  For example, in 
vitro co-crystallization and co-purification and in vivo two-hybrid studies are best 
suited for probing stably associated proteins, but are less ideal for studying 
proteins that engage in modest affinity and/or transient multi-protein binding 
interactions.12-16  Thus, the limitations of the current methods demonstrate a 
                                                          
2
 Portions of this chapter are from two published manuscripts. (1) Krishnamurthy, M.; 
Dugan, A.; Nwokoye, A.; Fung, Y.-H.; Lancia, J. K.; Majmudar, C. Y.; Mapp, A. K. ACS Chem Biol 2011, 
6, 1321. and  (2) Lancia, J. K.; Nwokoye, A.; Dugan, A.; Pricer, R.; Joiner, C.; Mapp, A. K. 
Biopolymers 2013, manuscript accepted. 
 The individual contributions to the data presented in this chapter are as follows:  Dr. Malathy 
Krishnamurthy was responsible for the creation and testing of LexA+VP16C constructs as well as the 
design and creation of the Swi1 and Snf5 deletion strains.  Amanda Dugan created and tested the 
LexA+VP16N constructs.  Hugo Fung and Adaora Nwokoye tested crosslinking of Gcn4 and Gal4, 
respectively, to Snf2.  Cassandra Joiner and Amanda Dugan designed and created the LexA+Gal4 
F856Bpa/Azpa methionine mutants and, along with Rachel Pricer, tested the incorporation, activity, and 
crosslinking of Bpa and Azpa mutants. Dr. Chinmay Majmudar provided intellectual contributions. 
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need for approaches that can probe these interactions in their native cellular 
environment.   
In this chapter, we address this issue by employing an in vivo photocrosslinking 
method that uses a genetically incorporated unnatural amino acid, p-benzoyl-L-
phenylalanine (Bpa).  We demonstrate the utility of this method in capturing the 
moderate affinity binding partners of the prototypical activator VP16 in live yeast, 
with particular focus on a previously identified putative interaction with Med15.   
Furthermore, in vivo photocrosslinking is used to examine the shared targets of 
amphipathic activators in yeast, including low abundance complexes such as the 
chromatin-modifying coactivator complex Swi/Snf.  Specifically, we capture 
subunits within the Swi/Snf complex that may serve as a common handle for 
activators during recruitment of this complex in cells. Furthermore, using the 
interaction between the yeast activator Gal4 and its suppressor Gal80 as a 
model, we address some factors that should be considered when interpreting 
negative results of crosslinking experiments (i.e. when crosslinking to a target is 
not observed), such as the positional context of the crosslinker as well as 
differential reactivities of the crosslinking moieties.  Taken together, the data 
presented in this chapter demonstrates the utility of genetically encoded photo-
activatable amino acids in characterizing activator-coactivator complexes in vivo 
and further suggests that this strategy can be implemented more broadly for the 
capture and discovery of transient protein-protein interactions in their native 
environment. 
2.B. Background : Activator-coactivator complex formation 
Transcriptional activators are signal responsive regulatory proteins that assemble 
the transcriptional machinery at the promoter of a gene through dynamic binding 
interactions with a variety of coactivator complexes, including chromatin-
modifying, helicase, and scaffolding complexes.11,17,18  Activators are modular in 
architecture and are minimally composed of a DNA binding domain (DBD) that 
localizes the activator to its cognate DNA binding site and a transcriptional 
26 
 
activation domain (TAD) that mediates the majority of contacts with 
transcriptional complexes.  Based on biochemical data, we know that the 
interactions between activators and suppressor proteins tend to be high affinity 
and specific in nature whereas activator-coactivator interactions appear to be 
mediated through lower affinity transient contacts (Figure 2-1).11,16,18-21  As 
mentioned in Chapter 1, this characteristic of activators has made the study and 




Figure 2-1 (a) The transcriptional activation domain (TAD) of amphipathic activators can engage in high 
affinity interactions, such as those with masking proteins (mp), but the interactions between the TAD and 




 (b) Amphipathic 
activators share little sequence homology but do share binding targets, at least in vitro.  The 
photocrosslinking amino acid, Bpa, has been incorporated within the Gal4 TAD (positions of incorporation 




In vivo co-localization studies have broadly defined the complexes that are 
recruited by amphipathic activators during transcription but have not readily 
provided information on the specific, direct coactivator targets within these 
complexes.22-24  For example, the well-characterized amphipathic activator VP16 
has been shown to recruit the Swi/Snf chromatin-remodeling complex early in 
transcription initiation, as evidenced by both in vivo and in vitro co-localization 
studies.25-30 In vitro assays have identified several subunits within this complex 
as possible targets of VP16 but in vivo interaction studies have not distinguished 
with of the components are the relevant binding partner(s) in cells.19,31,32  
Additionally, the results of in vitro binding studies do not always guarantee a true 
interaction in vivo.  The intrinsically disordered nature of amphipathic TADs, 
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combined with their hydrophobic amino acid composition, affords them a 
promiscuous binding profile, particularly in vitro.  In vitro binding experiments with 
the activator Gal4 identified several subunits within the transcriptional machinery 
as putative targets, but this approach also identified bacterial lysozyme as a 
binding partner, an unnatural interaction whose relevance in cells is non-
existent.33  As such, in vivo methodologies that can capture transient activator-
coactivator interactions in their native environment would be extremely beneficial 
in identifying the relevant cellular binding partners of transcriptional activators.  
2.C. Covalent chemical capture in cells 
Covalent chemical capture using genetically incorporated photocrosslinking 
amino acids such as Bpa is a promising tool in the identification of directly 
interacting PPIs in cells.  This approach requires the development of a nonsense 
suppression strategy to incorporate Bpa site-specifically into proteins in living 
cells and, upon irradiation of these cells, capture the direct targets of Bpa-
containing proteins.  Development of this strategy was initiated by the Schultz lab 
and then further optimized by the Mapp group, totaling over two decades of 
development efforts to make this a feasible strategy for the in vivo capture of 
activator targets in yeast.17,34  Briefly, incorporation of Bpa into proteins in yeast 
is accomplished using a Bpa-specific tRNA synthetase (BpaRS), derived from 
wild type E. coli Tyrosyl RS, to selectively charge a tRNA variant whose anti-
codon loop matches that of an amber stop codon (UAG) in the mRNA being 
translated.  Thus, mutation of specific codons in the open reading frame of a 
gene to an amber stop codon allows for Bpa to be site-selectively incorporated in 
the protein of interest.  Furthermore, the tRNABpa and BpaRS react bio-
orthogonally, therefore the BpaRS does not acylate natural tRNAs with Bpa and 
the tRNA Bpa should not be charged with natural amino acids by either 




Figure 2-2 Nonsense suppression allows genetic incorporation of unnatural amino acids (UAAs) into 
proteins and peptides. Successful expression of a protein (or peptide) with a UAA incorporated site 
specifically requires a tRNA/aminoacyl tRNA synthetase pair (red and blue, respectively) that recognizes a 
rare stop codon such as the AUG amber stop codon during the translation process. In order for incorporation 
to be selective, the tRNA/aminoacyl tRNA synthetase pair must be orthogonal to the tRNA/aminoacyl 
synthetase pairs that install the canonical amino acids. 
2.C.1. In vivo photocrosslinking in Saccharomyces cerevisiae 
In early work pioneered by the Schultz lab, Bpa incorporation in yeast was first 
demonstrated to occur in high yields and with high fidelity as measured by 
expression of the highly abundant and well-expressed protein, superoxide 
dismutase.34  However, as documented by our lab, transfer of this technology to 
more challenging protein systems required extensive optimization to increase 
overall mutant protein expression and ultimately support a more global 
application of this technology in yeast.2,17  These studies found that expression of 
the Bpa tRNA/RS pair could be increased by placing it under the control of a Pol 
III pSNR52 promoter, thus enhancing incorporation of Bpa in the activator Gal4 
as a result of increased Bpa tRNA/RS availability.  Furthermore, unlike other 
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promoters tested to achieve this result, the pSNR52 promoter was able to drive 
expression of the tRNA/RS without impacting the fidelity of the system.  Using 
this optimized system, Dr. Chinmay Majmudar and colleagues in our lab found 
that Bpa could be incorporated into TADs with high yields and with little impact 
on transcriptional activator binding and function.   
Once the optimal incorporation conditions were determined, our group next 
performed crosslinking experiments to evaluate if the in vivo binding partners of 
Gal4 could be captured using this approach.  Bpa is advantageous for in vivo 
studies as it can be activated at longer UV wavelengths (~365 nm), thus reducing 
the amount of protein and DNA damage that can occur as a result of irradiation 
at higher energy wavelengths.  Photoactivation of Bpa at 365 nm leads to the 
covalent capture of the direct binding partners of the activators which can then be 
isolated from yeast lysates after breaking irradiated cells open and analyzed by 
immunological methods such as Western blotting (as discussed in Chapters 2 
and 3) or by mass spectrometric methods (as discussed in Chapter 4) (Figure 
2-3).  
Crosslinking studies our group and others went on to demonstrate that in vivo 
crosslinking with Bpa is a useful method for capturing direct, high-affinity 
PPIs.17,36-38  More specifically, Bpa placement within the TAD of the activator 
Gal4 did not impair function of the protein and photoactivation led to covalent 
capture of its high affinity (low nanomolar KD) suppressor protein Gal80.
17 
However, while successful in the case of a very tight PPI, this method has not 
been employed in the case of moderate-affinity, transient interactions such as 
those between activators and coactivators.  In the following sections, we test the 
utility of in vivo Bpa crosslinking in capturing VP16-coactivator interactions and 





 Figure 2-3 . Schematic of in vivo photocrosslinking in yeast with Bpa.  Bpa is incorporated into the TAD of 
an activator in live yeast using nonsense suppression.  These yeast cells are then irradiated with UV light 
(365 nm) to activate the Bpa, leading to covalent capture of direct binding partners through C-H insertion 
chemistry.  The cells are then lysed and the covalent adducts are isolated using a variety of purification 
methods.  The identity of the crosslinked partner can then be identified through traditional immunological 
detection methods such as Western blotting or resolved by mass spectrometric methods to identify novel 
binding partners of transcriptional activators.  
2.D. The viral activator VP16 
During lytic infection of the herpes simplex virus (HSV-1), the amphipathic 
activator VP16 upregulates the expression of immediate-early genes required for 
the replication and survival of the virus.39  As expected for such a critical viral 
protein, VP16 is a powerful activator, able to initiate transcription rapidly and 
efficiently.40  In contrast to many other amphipathic activators, VP16 lacks a 
covalently bound DBD, instead using its core domain to bind two host proteins, 
Oct1 and Hcf1, to largely mediate its contact with DNA.41  Functional experiments 
on the VP16 TAD reveal that the full TAD (413-490) is actually comprised of two 
sub-domains that can function independently from one another, an amino 
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terminal VP16N (residues 413-456) and a carboxy terminal VP16C (residues 
446-490) (Figure 2-1,b).42,43   Further analysis of VP16N identified a minimal 
peptide sequence (DFDLDMLG) that was sufficient to activate transcription when 
tethered to a DNA binding moiety, with transcriptional activity increasing as 
multiple copies of the peptide were introduced.44-48  As such, experiments 
focusing on VP2, an activation domain bearing two copies of the DFDLDMLG 
sequence, yielded significant insights on how natural activators function.  
Biochemical studies with VP2 and each subdomain of VP16 have identified a 
multitude of putative binding partners, such as general transcription factors 
including TBP and its associated TAFs as well as components of the Mediator, 
SAGA, and Swi/Snf complexes, among others.24,26,27,29,32,49-67  However, given 
the largely in vitro context of these experiments, the role of important factors 
including coactivator dynamics and localization, chromatin organization, and 
proteasomal regulation remains untested under these conditions.  Therefore, 
while numerous putative binding partners of VP16 have been identified, the direct 
targets of VP16 in the native cellular context remains unclear.  
2.D.1. Incorporation of Bpa in the VP16 TAD 
To discover proteins that interact with different regions of the VP16 TAD in vivo, 
we incorporated Bpa within regions of each subdomain shown to be involved in 
forming protein interactions (VP16N: L439, F442, L444; VP16C: F473, F475, 
F479).43,68,69  Each Bpa-containing construct was expressed in Saccharomyces 
cerevisiae as a fusion protein bearing the bacterial LexA DBD and a carboxy-
terminal Flag tag for detection (Figure 2-4,a).   All six Bpa mutants were assayed 
for Bpa incorporation and activation potential in a yeast strain with an integrated 
LacZ reporter gene under the control of a GAL1 promoter bearing two LexA 
binding sites (Figure 2-4 b, c).  Therefore, the advantage of using a heterologous 
activator construct is that a single promoter containing binding sites for LexA 
exists within the yeast strain used in our studies, thus simplifying functional 
analyses of all mutant proteins.  As in previous studies, we found that efficient 
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Bpa crosslinking was affected by positioning of Bpa within the protein.17,70 As 
such, the LexA+VP16C F479Bpa mutant was removed from further testing as it 
displayed poor incorporation.  LexA+VP16N L444Bpa and LexA+VP16C 
F475Bpa, on the other hand, showed good incorporation and activity (Figure 2-4 
b, c), demonstrating that these two constructs were the most suitable for use in 
crosslinking experiments.  We subsequently examined the crosslinking profiles of 
each of these constructs and found that, as expected, each maintains a multi-
protein binding profile, with several covalent crosslinked complexes detected by 
Western blot (Figure 2-5).  Additionally, these crosslinking profiles were 
consistently repeatable; as a result, these two constructs were selected to be the 
focus of additional crosslinking investigations.  
 
Figure 2-4 Incorporation of Bpa within the VP16 TAD. (a) Plasmids encoding the DNA binding domain (DBD) 
of LexA fused to either the N- or C-terminal VP16 TAD as well as a FLAG tag were constructed.  The LexA 
DBD was utilized to exclusively examine transcriptional activation at the 2 unique LexA binding sites 
upstream of the LacZ reporter in S. cerevisiae.  Positions at which Bpa mutagenesis was carried out are 
within regions of the VP16N or VP16C subdomains known to participate in coactivator binding (sites of 
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incorporation highlighted in red).  (b) Yeast cells bearing plasmids encoding the various LexA+VP16 
constructs and the Bpa specific tRNA/synthetase pair expressed by pSNRtRNA-pBpaRS were grown in the 
presence or absence of 1 mM Bpa and analyzed by Western blot with an -Flag antibody (c) LexA+VP16N 
L444Bpa and LexA+VP16C F475Bpa were assessed for their ability to upregulate transcription of an 
integrated LacZ reporter gene in S. cerevisiae as measured by liquid b-galactosidase assays.  Each activity 
is the average of values from at least three independent experiments with the indicated error (SDOM). Dr. 
Malathy Krishnamurthy performed experiments with LexA+VP16C and Amanda Dugan performed 
experiments with LexA+VP16N. 
 
   
Figure 2-5 Photocrosslinking profiles of LexA+VP16N and LexA+VP16C Bpa containing mutants.  Bpa was 
incorporated in LexA+VP16N (left) at positions 439, 442, and 444 and in LexA+VP16C (right) at positions 
473, 475, and 479 in yeast.  Yeast cells were irradiated with UV light for 30 minutes on ice to activate Bpa 
and covalently capture proteins directly binding to each subdomain of Bpa.  Western blot is visualized with 
an -FLAG antibody.  Dr. Malathy Krishnamurthy carried out experiments with LexA+VP16C and Amanda 
Dugan carried out experiments with LexA+VP16N. 
2.D.2. Capturing VP16-Med15 in live yeast: a model moderate affinity interaction 
 A strong body of evidence exists to support the Mediator subunit and 
coactivator Med15 as a target of VP16 and this model that is supported by in vivo 
deletion and mutagenesis experiments from our own lab.18,70  The interaction 
between Med15 and activators such as VP16 is moderate in affinity (high nM to 
low M) with dissociation constants 2 orders of magnitude weaker than the 
Gal4-Gal80 interaction (Figure 2-6 a).17,18,70,71  Thus, this interaction appeared to 
be an excellent test case of the effectiveness of the in vivo crosslinking strategy 
for capturing moderate affinity binding interactions.  We first tested the ability of 
each VP16 subdomain to crosslink to the coactivator Med15 in vivo by co-
expressing myc-tagged Med15 alongside either LexA+VP16N L444Bpa or 
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LexA+VP16C F475Bpa and irradiating live yeast with 365 nm UV light.  The 
covalent adducts were isolated from yeast lysate and analyzed by Western blot 
(Figure 2-6 b).  A direct contact between each subdomain of VP16 and Med15 
was observed and this was dependent upon irradiation, thus validating the utility 
of this method in capturing a moderate affinity in vivo interaction of a 
transcriptional activator. 
 
Figure 2-6 In vivo photocrosslinking captures the moderate affinity interaction between LexA+VP16 and the 
Mediator protein, Med15.  a) VP16 has been shown to interact transiently with the coactivator Med15, with 
equilibrium binding measurements placing the affinity of the TAD for Med15 in the moderate category. DNA-
bound homodimers exhibit the highest affinity (0.1 M) for Med15 and isolated TADs display affinities for 
Med15 that falls in the low to mid-micromolar range (16, 44). (b) Live yeast cells bearing plasmids 
expressing LexA+VP16N L444Bpa or LexA+VP16C F475Bpa fusion proteins, in addition to a plasmid 
expressing myc-Med15(1-416) were irradiated with UV light (365 nm) for 30 minutes.  Subsequently, cell 
lysates were immunoprecipitated with -LexA and analyzed by Western blot (-myc).  For both constructs, a 
crosslink with Med15 is observed. Dr. Malathy Krishnamurthy performed experiments with LexA+VP16C and 
Amanda Dugan performed experiments with LexA+VP16N. 
2.D.3. Capturing the direct interactions of VP16 within the Swi/Snf chromatin 
remodeling complex 
As outlined earlier, the Swi/Snf chromatin-remodeling complex has also been 
proposed to be a direct binding partner of activators such as VP16 but there is 
conflicting evidence as to which subunit(s) serves as the activator-binding motif 
in vivo.  In yeast, Swi/Snf is a twelve subunit multi-protein complex that, when 
recruited to promoters such as GAL1, enhances transcription by repositioning 
nucleosomes and increasing transcription factor accessibility at the promoter.  As 
discussed in Chapter 1, the activity and localization of many transcriptional 
complexes including Swi/Snf are modulated by the presence of subunits that can 
associate either stably or transiently with the complex.  For example, the human 
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homolog of the Swi2/Snf2 ATPase, Brg1/BRM, has been shown to function 
independently but its activity is enhanced significantly upon addition of three 
other subunits (INI1 (ySnf5), BAF155 (ySwi3), and BAF170 (ySwi3)). The direct 
effects of the exchange of these subunits can be seen during neuronal 
development, where modulation of the complex results in the differentiation of an 
embryonic stem cell into a fully developed neuron. In yeast, VP16 enhances 
Swi/Snf recruitment to promoters such as GAL1 used in our studies and 
structural studies of Swi/Snf in complex with the nucleosome suggest that the 
catalytic subunit Snf2 is positioned close to the activator.25-30,72-74  However, in 
vitro binding studies have shown that several additional subunits can serve as 
activator binding partners (Swi1, Snf5).19,31,32  We hypothesized that the in vivo 
crosslinking strategy could be used to test if the Swi/Snf complex is directy bound 
by VP16 in the cell and, if so, to identify the Swi/Snf subunits that are directly 
bound by VP16 in the native complex environment.  We secondly wished to 
identify which subdomain was important for binding these subunits, thus 
revealing a more complete picture of recruitment by VP16 in vivo.   
2.D.4. VP16 and the Snf2 ATPase 
In the case of both the LexA+VP16N L444Bpa and the LexA+VP16C F475Bpa 
activators, irradiation of live yeast cells expressing the activators followed by 
visualization of all crosslinked products via immunodetection of the FLAG tag 
revealed several bands in the 130-220 kDa molecular weight range, consistent 
with the size range expected for covalent complexes with the Snf2, Swi1, and 
Snf5 subunits (Figure 2-7 c,d).  To test this, immunoprecipitation of whole-cell 
extracts from irradiated cells with an antibody to Snf2 was carried out.  In these 
experiments, no detectable LexA+VP16N-Snf2 product was observed, even 
when additional Bpa incorporation positions at L439 and F442 were tested (data 
not shown).  However, as seen in Figure 2-7b, the LexA+VP16C F475Bpa 
mutant crosslinks directly to endogenous Snf2.  Consistent with this result, point 
mutations (F479A and F479P) known to decrease VP16 coactivator binding in 
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vitro were introduced and, in line with these earlier biochemical experiments, 
abrogation of VP16 crosslinking to Snf2 in vivo is observed.55,59,62  These results 
are consistent with the recent structural model proposed by Dechassa et al that 
places Snf2 proximal to the transcriptional activator in the context of a Swi/Snf-
nucleosome-activator complex.30  Further, the data suggests that it is the C-
terminus of the VP16 TAD that is responsible for the bulk of the Snf2 recruitment 
activity.  
 
Figure 2-7 Analysis of VP16 crosslinking to the Swi/Snf coactivators, Snf2, Swi1 and Snf5.  (a) The 
recruitment of the Swi/Snf chromatin remodeling complex by VP16 has been proposed to occur through 
interactions with the Snf2, Swi1 and Snf5 subunits although the direct binding partners in vivo have not been 
determined (17, 33, 34). (b) Live yeast cells expressing LexA+VP16C F475Bpa were irradiated with 365 nm 
light (30 minutes) and subsequently the cell lysates were immunoprecipitated with an antibody to Snf2 and 
resolved by Western blot (-FLAG), revealing a direct interaction between VP16C and endogenous Snf2.  In 
line with previous biochemical experiments, when phenylalanine 479 in VP16C was mutated to either 
alanine or proline, crosslinking to Snf2 was abolished. (c,d) LexA+VP16C F475Bpa and LexA+VP16N 
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L444Bpa were expressed in yeast strains lacking either Swi1 or Snf5 and the live yeast cells were irradiated 
with 365 nm light.  Subsequently, cell lysates were immunoprecipitated (-LexA) and resolved by Western 
blot (FLAG).  In the individual blots for LexA+VP16N, the marks a and b denote crosslinked protein bands 
at the appropriate size for Swi1 and Snf5, respectively.  In the individual blots for LexA+VP16C, the marks c, 
d, and e indicate bands at the appropriate size for Snf2, Swi1 and Snf5, respectively. (e) To test if Gal4 also 
contacts Snf2, crosslinking experiments were carried out with live yeast cells expressing LexA+Gal4 
F867Bpa as in (b).  Dr. Malathy Krishnamurthy created the Swi/Snf deletion strains and performed 
crosslinking with LexA+VP16C, Amanda Dugan performed experiments with LexA+VP16N, Hugo Fung 
carried out experiments with LexA+Gcn4, and Adaora Nwokoye performed experiments with LexA+Gal4. 
2.D.5. VP16 and Snf5, Swi1 and Snf6 
In contrast to the Snf2 immunoprecipitation experiments, enrichment with either a 
Swi1 or Snf5 antibody did not result in any detectable crosslinked product (data 
not shown).  We realize that this could be one effect of crosslinking experiments 
in that, depending on the location of the crosslinked bond formed, epitope 
recognition by the antibody could be obscured in a similar fashion to what is seen 
in formaldehyde crosslinking experiments.  To probe these interactions further, 
we generated yeast strains lacking either Swi1 or Snf5 and carried out 
crosslinking experiments.  No differences in crosslinked product formation 
between the WT strain and the Swi1 delete strain were observed with either 
VP16-derived activator, suggesting that Swi1 is not a direct target of VP16 
(Figure 2-7c).  In contrast, deletion of Snf5 disrupts the normal binding pattern of 
LexA+VP16N L444Bpa, consistent with Snf5 interacting with VP16N (Figure 
2-7d).  However, upon deletion of Snf5, LexA+VP16C F475Bpa displays no 
change in binding pattern, implying that the VP16C TAD does not interact with 
Snf5.   
In vitro data does not strongly support an interaction between Snf6 and VP16 but 
the structural model of a VP16-Swi/Snf complex from EM studies suggests that 
the Snf6 subunit is the closest in proximity to the activator.30,32  As such, we 
decided to test if this subunit was involved in Swi/Snf recruitment.  In the 
absence of a commercially available antibody, we created a myc-Snf6 construct 
and co-expressed this alongside our VP16 Bpa mutants.  Following irradiation of 
cells with UV light, we lysed the yeast and immunoprecipitated the covalent 
activator adducts with a LexA antibody and probed the subsequent Western blot 
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with a myc-antibody to detect covalently bound Snf6.  To our surprise, a clean 
band corresponding to the molecular weight of a VP16N-Snf6 complex was 
detected, indicating that VP16N does in fact directly contact Snf6 in cells, despite 
earlier in vitro studies testing and missing the capture of this interaction (Figure 
2-8).  Together with the results of Figure 2-7b, these data support a model in 
which the subdomains of VP16 work cooperatively to recruit the Swi/Snf complex, 
with VP16C directly contacting Snf2 and VP16N depending on Snf6 and Snf5 
during transcription initiation. 
  
Figure 2-8 In vivo photocrosslinking captures the Swi/Snf subunit Snf6, an unlikely target according to in 
vitro studies.  LexA+VP16N L444Bpa and LexA+VP16C F475Bpa were co-transformed alongside myc-Snf6 
in yeast and subjected to in vivo photocrosslinking experiments as described earlier.  Immunoprecipitation of 
resulting cell lysates with a LexA antibody followed by Western blot detection with an -myc antibody 
reveals a direct interaction between each subdomain of VP16 and Snf6.  LexA+VP16C was not tested for 
crosslinking to Snf6.  The appearance of two bands in these experiments has been observed with other 
myc-tagged proteins including Med15.   Given the importance of ubiquitin mediated degradation in 
regulation activators, this lower band could be a partially degraded crosslinked product.  However, reports 
from other labs suggest that proteins that are heavily phosphorylated often display several bands on a blot. 
Thus, the two bands shown could indicate a crosslinked VP16N-Snf6 product, one that is more 
phosphorylated than the other.  
2.E. Examining shared targets of amphipathic activators in the Swi/Snf complex 
Snf2 is an ATPase that is essential for Swi/Snf function and is highly conserved 
among eukaryotes, making it a likely shared target among other transcriptional 
activators.75  In fact, in addition to VP16, the amphipathic activators Gal4 and 
Gcn4 have been shown to recruit Swi/Snf to a variety of promoters in vivo and in 
vitro, suggesting that these activators contact a conserved set of targets within 
this complex.19,29,31,76-80  To determine if Snf2 is a shared target of these 
activators, Gal4 and Gcn4 were modified to contain Bpa within regions of each 
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TAD implicated in coactivator binding and then tested for their ability to crosslink 
to Snf2.  As shown in Figure 2-7e, Gal4 makes a direct contact with Snf2, 
whereas Gcn4 does not for any position tested (Figure 2-9). These data suggest 
that Snf2 (Brg1/Brm in metazoans) could be a key target for small molecule 
probe development in order to characterize the role of the conserved Swi/Snf 
complexes that are associated with pathophysiological processes.81-84  However, 
further studies will be needed to dissect if VP16 and Gal4, as well as other 
activators, interact with the same binding site within Snf2.  Together, this data 
demonstrates the powerful advantage that in vivo photocrosslinking methods 
provide in capturing the direct cellular binding partners of transcriptional 
activators, as demonstrated by the identification of Swi/Snf targets that were 
missed by in vitro studies.  
 
Figure 2-9 LexA-Gcn4 does not appear to crosslink to Snf2 in vivo. Live yeast cells expressing LexA+Gcn4 
W120Bpa were irradiated with 365 nm light for 30 minutes. (a) Cell lysates were immunoprecipitated with an 
antibody to LexA and resolved by Western blot (-FLAG), indicating multiple crosslinked products.  (b) Cell 
lysates were immunoprecipitated with an antibody to Snf2 and resolved by Western blot (-FLAG).  Similar 
results were obtained with LexA+Gcn4 with Bpa incorporated at positions F108, Y110, D115, K118, T121, 
L123, F124, N126, T132 or K140. 
2.F. Considerations when interpreting a negative crosslinking result 
Through these studies, we have found that it is difficult to interpret a negative 
result from in vivo photocrosslinking studies.  A negative result, as in the case of 
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the Swi1 and others, could arise from a variety of factors including lack of a 
binding interaction, low unnatural amino acid (UAA) incorporation yield and/or 
fidelity, poor positioning of the UAA, and the poor reactivity of the activated UAA 
with the amino acids in the binding partner.  As a case in point, the first example 
of in cell photocrosslinking experiments from our group led to the in situ 
characterization of the binding interface between Gal4 and its masking protein 
Gal80. In these experiments, Majmudar et al incorporated Bpa at positions 
spanning the Gal4 TAD and then carried out crosslinking experiments with these 
mutants to capture the Gal4-Gal80 interaction in yeast.   From the results, they 
noticed that for position 856, significant functional and structural data exists to 
support the involvement of this residue in a direct Gal4-Gal80 interaction yet little 
to no crosslinking was observed.17 However, the LexA+Gal4 F856Bpa mutant 
remained repressed in the presence of Gal80, indicating that incorporation of 
Bpa at this position did not negatively impact the Gal80 binding interaction.  Thus 
we launched an examination of the remaining facets of the in vivo crosslinking 
experiment and, importantly demonstrate the substantial role that the crosslinking 
mechanism and sequence context play in the ability to capture a PPI.  This case 
study of a PPI provides an additional framework for designing successful in vivo 
crosslinking experiments.  
2.F.1. The Gal4-Gal80 interaction 
In response to carbon source availability, the well-characterized yeast activator 
Gal4 regulates genes responsible for galactose catabolism and its function is 
highly regulated by its masking protein Gal80.85-88  In the presence of glucose, 
Gal80 binds Gal4 with low nanomolar affinity and prevents Gal4 from recruiting 
the necessary transcriptional complexes to upregulate gene expression.71  
Conversely, in the absence of glucose and presence of galactose, inhibition of 
Gal4 by Gal80 is lifted, allowing transcription to occur.  Functional and structural 
data have mapped the residues in Gal4 involved in contacting Gal80 and thus 
which residues were most likely to yield crosslinks in our photocrosslinking 
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studies.71,88-91  As in earlier experiments, a heterologous construct, LexA+Gal4-
flag was used in these studies. 
As described earlier, in vivo photocrosslinking with LexA+Gal4 F856Bpa yielded 
no complex between Gal4 and Gal80 despite several lines of evidence 
supporting an interaction.  Bpa incorporation at this position was evaluated and 
subsequent Western blot analysis and functional data indicated that LexA+Gal4 
F856Bpa was not only being expressed, but that it was also fully functional and 
sensitive to Gal80 inhibition under glucose conditions.  
2.F.2. Differences in Bpa and Azpa crosslinking mechanism and reactivity 
On explanation for the failure to capture Gal80 is intramolecular quenching of 
Bpa. Upon irradiation with 350-365 nm UV light, Bpa forms a diradical that 
proceeds to form a covalent bond with nearby protein backbones and amino acid 
side chains through C-H insertion chemistry.13 Although Bpa can react with most 
C-H bonds, it has experimentally been shown to react preferentially with 
methionine (Met) where it reacts at distances beyond the 3.1 A reactive radius.92  
Specifically, the apparent preference of Bpa for methionine suggests that Bpa 
efficiency can be altered dramatically when placed in close proximity to 
methionine’s thioether side chain.92-94  Further analysis of position 856 in the 
Gal4 TAD reveals two methionines in close proximity to the Bpa side chain, thus 
we hypothesized that the methionine residues at positions 855 and 861 are 
internally “quenching” Bpa, thereby preventing it from crosslinking to Gal80. 
Consistent with this hypothesis, when Met855 and Met861 are mutated either 
individually or collectively to alanine, we see that the resulting mutants are 
functional and, importantly, that crosslinking of Gal4 to Gal80 is restored (Figure 
2-11).  These data are consistent with a model in which an intramolecular 
crosslink was competing with the intermolecular reaction in the LexA+Gal4 




Thus a different photoactivatable amino acid, Azpa, was used as this can be 
incorporated into proteins in yeast using the optimized nonsense suppression 
system.  The amino acid preference for Azpa crosslinking is less clear because it 
has a more complex crosslinking mechanism compared to Bpa.13  During 
excitation at ~254 nm of light it forms a nitrene that can then insert into C-H or 
heteroatom-H bonds.  However, if the nitrene does not react within the ~10-4 s 
excitation, it will rearrange into a more stable ketenimine which can then react 
with nucleophiles, including surrounding solvent.13,95  Although the differences in 
reactive mechanism between Bpa and Azpa are known, a direct comparison of 
the effect of these reactivities on the experimental outcome of crosslinking 
studies has yet to be established.  
 
Figure 2-10 (top) Azpa crosslinking mechanism.  Upon irradiation with ~254 nm UV light, Azpa forms a 
nitrene that can form covalent crosslinking adducts with nearby C-H and N-H bonds.  In the absence of a 
crosslinking partner, the nitrene relaxes into a ketenimine that then reacts with nucleophiles such as primary 
amines to form a stable end product.  Once activated, Azpa cannot relax back to its ground state and be 
reactivated for crosslinking investigations.  (b). Bpa crosslinking mechanism.  Upon irradiation with 350-365 
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nm UV light, Bpa forms a diradical that can relax back down to its ground state (reversible excitation).  





Figure 2-11 Evaluating intramolecular quenching of Bpa in LexA+Gal4 F856Bpa by neighboring methionines 
at residues 855 and 861. (a). M855 and M861 in the Gal4 TAD were individually and collectively mutated to 
alanine to remove the presence of the thioether side chain that has been shown to have a “magnet” effect 
on Bpa crosslinking.  Incorporation of Bpa in LexA+Gal4 F856Bpa and the methionine mutants was tested 
as described earlier, showing the production of full-length protein for each construct. (b). All mutants were 
tested for functional output as measured by liquid -galactosidase assays.  Activator activity was measured 
as a function of expression of an integrated LacZ reporter gene under the control of a GAL1 promoter 
bearing two LexA binding sites.   All constructs maintained sensitivity to glucose repression and galactose 
induction. (c).  Mutants were assayed for ability to crosslink to myc-Gal80 in live yeast.  As discussed in the 
text, LexA+Gal4 F856Bpa is unable to form crosslinks with myc-Gal80 despite functional and structural 
evidence implicating this residue in the interaction face.  Upon mutation of neighboring methionines to 
alanine, crosslinking to Gal80 is restored, indicating a probable intramolecular quenching by positions 855 
and 861 in the Gal4 TAD. Experiments performed alongside Rachel Pricer and Cassandra Joiner in the 
Mapp Lab.   
2.F.2.a. Impact on UAA reactivity on the outcome of crosslinking studies   
Here we incorporate Azpa into the Gal4 TAD using the same optimized system 
developed by our lab for Bpa incorporation.  As before, Azpa incorporation is 
driven by an Azpa specific tRNA/RS whose expression is controlled by the 
pSNR52 promoter.  Utilization of the expression conditions outlined earlier leads 
to the incorporation of Azpa at position 856, with the resulting mutant proving to 
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be fully expressed and functional (Figure 2-12a,b).  We next performed a direct 
comparison of Azpa and Bpa at postion 856, revealing that LexA+Gal4 
F856Azpa readily crosslinks to Gal80 whereas LexA+Gal4 F856Bpa does not.  
As expected, switching methionine for alanine at positions 855 and 861 yielded 
no changes in Azpa crosslinking, consistent with the reactivity profile of this 
amino acid (Figure 2-12c).  Thus, we find that to avoid false negatives, one 
should carry out crosslinking experiments with more than one UAA mutant since 
a small change in position can have a dramatic effect on crosslinking outcome.  
The results shown with Gal4-Gal80 illustrate that careful consideration of the 
innate reactivity of the UAA utilized is a key factor in the successful application of 
the in vivo photocrosslinking strategy. 
 
Figure 2-12 Azpa crosslinks to myc-Gal80 regardless of the presence of neighboring methionines. (a). M855 
and M861 in the Gal4 TAD were individually and collectively mutated to alanine to remove the presence of 
the thioether side chain that has been shown to have a “magnet” effect on Bpa crosslinking.  Incorporation of 
Azpa in LexA+Gal4 F856Azpa and the methionine mutants was tested as described earlier, showing the 
production of full-length protein for each construct. (b). All mutants were tested for functional output as 
measured by liquid -galactosidase assays.  Activator activity was measured as a function of expression of 
an integrated LacZ reporter gene under the control of a GAL1 promoter bearing two LexA binding sites.   All 
constructs maintained sensitivity to glucose repression and galactose induction. (c).  Mutants were assayed 
for ability to crosslink to myc-Gal80 in live yeast.  In contrast to studies with Bpa, LexA+Gal4 F856Azpa 
readily forms crosslinks with myc-Gal80.  Mutation of neighboring methionines to alanine does not appear to 
effect LexA+Gal4 F856Azpa crosslinking to Gal80, consistent with the crosslinking mechanism of Azpa.  




Taken together, these data demonstrate that the genetically encoded 
photocrosslinkers Bpa and Azpa are a viable and perhaps indispensible tool for 
capturing moderate affinity and transient protein-protein interactions in cells.  
Employing the in vivo photocrosslinking strategy revealed an interaction model 
for the cooperative recruitment of the chromatin-remodeling Swi/Snf complex to 
gene promoters and further identified the Snf2 coactivator and ATPase to be a 
direct target of the prototypical activators VP16 and Gal4.  These data represent 
a significant step toward the development of a complete interaction map of the 
direct binding partners of transcriptional activators, long an elusive goal.  
Furthermore, applying the considerations presented in this chapter will facilitate 
the successful implementation of the in vivo crosslinking methodology for this 
class of moderate affinity, transient interactions and further sets the stage for the 
dissection of the complex interactions of the many other cellular mechanisms that 
function through similar PPI networks.  
2.G. Experimental 
Yeast Strain LS41 [JPY9::pZZ41, Mata  his3Δ200  leu2Δ1  trp1Δ63  ura3-52 
lys2Δ385  gal4 URA::pZZ41] was used for the crosslinking experiments. Swi1 
and Snf5 deletion strains were made by gene disruption via PCR in LS41 and 
used for deletion crosslinking experiments. pBpa was purchased from Chem-
Impex International (Wood Dale, IL). All plasmids described below were 
constructed using standard molecular biology techniques. The sequences of all 
the isolated plasmids were verified by sequencing at the University of Michigan 
Core Facility (Ann Arbor, MI). 
 
Table of Plasmids used in this Chapter 




pLexAVP16N Expresses LexA(1-202)+VP16 (413-
456)+FLAG tag 









490)+FLAG tag with a TAG replacing 









456)+FLAG tag with a TAG replacing 
the codon of the existing amino acid 
 
pLexAGal4  849TAG, 
pLexAGal4 867TAG, 
pLexAGal4      869TAG 
 
Expresses LexA(1-202)+Gal4(840-
881)+FLAG tag with a  TAG replacing 












144)+FLAG tag with a TAG codon 




pLexAGcn4   140TAG 
pSNRtRNA-pBpaRS Expresses tRNA under the control of 
the SNR52 promoter and contains 
synthetase specific for pBpa ptRNA-
pBpaRS 







881)+FLAG tag with a TAG replacing 
the codon of the existing amino acid 
pSNRtRNA-pAzpaRS  Expresses tRNA under the control of 
the SNR52 promoter and contains 
synthetase specific for pAzpa 




Construction of plasmids 
1. pLexAVP16 N and pLexAVP16C 
A high copy plasmid expressing LexA(1-202)+VP16N (413-456)+FLAG tag and 
LexA(1-202)+VP16C (446-490))+FLAG tag under the control of the ADH1 
promoter was created from pCLexA containing EcoRI and BamHI sites.  Primers 
5’- catgaattcATGGCCCCCCCGACCGATGTC-3’ and 5’-
catggatccTTACTTGTCATCGTCGTCCTTGTAGTCTCCCGGCCCCGGGGAATC
CC-3’ 
were used to amplify VP16 (413-456) using pMVP16 as a template.  The 
amplified PCR product was digested with EcoRI and BamHI and inserted into 
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pCLexA digested with EcoRI and BamHI and treated with calf intestinal 
phosphate to create pLexAVP16N.   
Primers 5’ catgaattcATGTTGGGGGACGGG- 3’ and (5’-
catggatccTTACTTGTCATCGTCG -3’) were used to amplify VP16 (446-490) 
using pMVP16 as a template.  The amplified PCR product was digested with 
EcoRI and BamHI and inserted into pCLexA digested with EcoRI and BamHI and 
calf intestinal phosphate treated to create pLexAVP16C. 
 
2. pLexAVP16N 439TAG, pLexAVP16N 442TAG, pLexAVP16N 444TAG, 
pLexAVP16C 473TAG, pLexAVP16C 475TAG, pLexAVP16C 479TAG 
Plasmids containing various amber mutants in the VP16 TAD were derived from 
pLexAVP16N and pLexAVP16C. To create each plasmid, site-directed 
mutagenesis was used to replace an existing amino acid codon with TAG codon 
within the VP16C or VP16N TAD. In general, PCR primers were designed to 
have ~15 bases of homology on either side of the TAG mutation. QuikChange 
(Stratagene, La Jolla, CA) was used to incorporate the TAG mutants using 
manufacturer recommended conditions. 
3. pLexAGcn4(107-144) 
In a similar fashion to the VP16 plasmid construction, a high copy plasmid 
expression LexA(1-202)+Gcn4(107-144)+FLAG tag under the control of the 
ADH1 promoter was created from pCLexA containing EcoRI and BamHI sites. 
Primers 5’-GAATTCATGTTTGAGTATGAAAACCTAGAAGACAACTC-3’ and 5’-
GGATCCGGATTCA ATTGCCTTATCAGCCAATG-3’ were used to amplify 
Gcn4(107-144) from yeast genomic DNA.  The amplified product was digested 
with BamHI and EcoRI and then treated with Calf intestinal phosphatase to 
create pLexAGcn4. 
4. pLexAGal4 (840-881) 
pLexA(1-202)+Gal4(840-881) was created as previously described (Majmudar, 
CY et al, 2009) 
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5. pMycMed15 (1-416) 
A high copy plasmid pMycMed15(1-416) expressing Med15(1-416) under the 
ADH1 promoter, N-terminally tagged with the c-Myc epitope was constructed by 
amplifying the DNA sequence encoding Med15(1-415) from yeast genomic DNA 
using primers (5’-GACAGGATCCATGTCT GCTGCTCCTGTCCAAGAC-3’) and 
(5’- CGATCATATGTCACTGATATAATTTAGAACTTGC-3’) and inserted into 
BamHI and NdeI digested pMyc using standard molecular biology techniques. 
The pMyc cloning vector was created by inserting an ADH1 driven c-myc epitope 
tag in pGADT7 (Clontech) followed by restriction sites for gene insertion using 









Round 1 PCR 
CATCAAGGGAACATATAGTAAAGAACTACACAAAAGCAACA 
CGGATCCCCGGGTTAATTAA 









Snf5-Rev-2 Round 2 PCR GATAATACAAATTCTTCCACGGTTATTTACATCTCCGGTA 







Construction of Snf5 and Swi1 delete strains 
The yeast delete strains were made by gene disruption via PCR using a method 
described earlier (Longtine, M. S et al, Yeast 14, 953–961 (1998)). All the delete 
strains were derived from LS41 [JPY9::pZZ41, Mata  his3Δ200  leu2Δ1  trp1Δ63  
ura3-52 lys2Δ385  gal4 URA::pZZ41]. Plasmid PFa6-TRP1 (generously donated 
by Karbstein group, University of Michigan) was used as a template to clone out 
deletion inserts using target-gene-specific primer pairs as designated in Table 2.  
Table 2: Primers used for PCR based gene deletion 
The underlined sequences correspond to the sequence on the pFa6-TRP1 
plasmid and the sequences in italics are gene specific sequences. The 
sequences in bold are Snf5 gene specific sequences and are ~ 20 bp upstream 
and downstream of Snf5 sequence from Round 1 PCR product.  
In case of Swi1 deletion, pFa6-TRP1 was used as template and PCR inserts 
were cloned out using primers Swi1-Fwd and Swi1-Rev. 1-5 ug of the PCR 
product was transformed into LS41 and spread on plates containing SC media + 
2% Glucose, lacking uracil and tryptophan.  After 3-4 days, the colonies grown 
were screened for deletion strains by lysing a small amount of the colony using 
20 mM NaOH.  Briefly, a small amount of the colony (~ 0.25-0.5 uL) was taken 
into a PCR tube containing 20 uL of 20 mM NaOH. The tube was boiled for 20 
min at 95 °C in a PCR machine and spun down. The supernatant (0.5 – 1 uL) 
was used as a template and using sequencing primers, the deletion was verified 
by gel electrophoresis and DNA sequencing. In case of the Snf5 deletion, there 
was no successful deletion with one round of PCR and hence a ~ 60 bp Snf5 






specific homologous sequence was cloned upstream and downstream of the 
Trp1 sequence by two rounds of PCR using primers described in Table 2.  
Screening and selection was done as described for Swi1 deletion and verified by 
DNA sequencing. 
 Incorporation of pBpa into LexA(1-202)+VP16N and LexA(1-202)+VP16C and 
expression of myc-Med15 in S. cerevisiae pellet 
LS41 yeast was transformed with various pLexAVP16 TAG mutant plasmids and 
pSNRtRNA-pBpaRS plasmid. Individual colonies were grown to saturation in 5 
mL SC media lacking histidine and tryptophan for selection and 2% Raffinose at 
30 °C, with agitation.  Starter cultures were then used to inoculate 5 mL SC 
media lacking histidine and tryptophan, containing 2% Raffinose and 2% 
Galactose. For pBpa incorporation, 50 L of 100 mM pBpa dissolved in 1M 
NaOH and 50 L 1M HCl were added to the above cultures.  The cultures were 
grown overnight at 30 °C, with agitation to an OD660 of ~1.0. 3 OD’s of cells were 
harvested and the cell pellets were lysed in 12 uL pellet lysis buffer (50 mM Tris 
Acetate, pH 7.9, 150 mM KOAc, 20% glycerol, 0.2% Tween-20, 2 mM MgOAc) 
containing complete EDTA free protease inhibitor tablets (Roche), 7 uL 1 mM 
DTT, and 7 uL 4X LDS NuPAGE dye (Invitrogen).  Lysates were boiled at 95 °C 
and analyzed using Western blot with anti-FLAG (M2) antibody (Sigma).  To test 
expression of the myc-Med15(1-416) construct, the same protocol was followed 
except that LS41 were additionally transformed with the pMyc-Med15(1-416) 
plasmid and grown in SC media lacking histidine, tryptophan and leucine.  
Lysates were analyzed using Western blot with anti-myc antibody (Santa Cruz 
Biotech, sc-40). 
In vivo cross-linking 
To perform in vivo cross-linking, individual colonies of each pLexAVP16 TAG 
mutant were grown in 5 mL SC media containing 2% Raffinose but lacking 
histidine and tryptophan for selection. The cultures were incubated overnight at 
30 °C with agitation. Following incubation, these cultures were used to inoculate 
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100 mL cultures of SC media containing 2% Raffinose and 2% Galactose. For 
pBpa incorporation, 1 mL 100 mM pBpa dissolved in 1M NaOH and 1 mL 1M HCl 
were added to the above cultures. For control cultures, 1 mL 1M NaOH  and 1 
mL 1M HCl were added. The cultures were incubated overnight at 30 °C with 
agitation to an OD660 of ~1.0. When cultures reached the appropriate OD660, the 
cells were spun down by centrifuging at 3901 rcf at 4oC for 5 min. following which 
the cell pellets were washed with SC media lacking histidine and tryptophan.  
The cell pellets were resuspended in 2mL SC media lacking histidine and 
tryptophan + 2% Raffinose, 2% Galactose and transferred to small cell culture 
dishes and subjected to UV irradiation at 365 nm light (Eurosolar 15 W UV lamp) 
with cooling for 0.5 h. The cells were isolated by centrifugation and stored at -
80oC until lysis.   
For crosslinking studies with mycMed15(1-416), myc-Snf6, myc-Gal80 and the 
deletion strains, the procedure was identical except that cells were grown in SC 
media lacking histidine, leucine, and tryptophan and, due to poor growth in 
raffinose and galactose, deletion cultures were grown in 2% glucose. For lysis, 
cells were resuspended in 600 μL Lysis buffer (50 mM HEPES-KOH pH 7.5, 140 
mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-Deoxycholate and 2X 
Complete Mini, EDTA Free Protease Inhibitor (Roche) and lysed using glass 
beads by vortexing at 4 °C. Subsequently, the lysate was pelleted and the 
supernatant incubated with 10 μL of LexA antibody (sc-1725, Santa Cruz 
Biotechnologies) for 2 h at 4 °C for immunoprecipitation. The protein bound to the 
antibody was isolated by incubation for 1 h with either ~50 μL of prewashed 
protein G magnetic beads (Dynal Corporation, Invitrogen, Carlsbad, CA) or ~ 25 
uL prewashed protein G agarose beads (Millipore) at 4 oC. After 
immunoprecipitation, the beads were washed 6 times with 1 mL Wash Buffer (10 
mM Tris-HCl pH 8.0, 250 mM LiCl, 0.5% NP-40, 0.1% Na-Deoxycholate and 1 
mM EDTA) and stored dry at -80 oC until elution. The crosslinked sample was 
eluted from the beads by heating at 95 oC for 10 min in NuPAGE 4x LDS Sample 
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buffer (Invitrogen, Carlsbad, CA) containing 250 mM DTT and probed using 
Western Blot analysis using anti-FLAG (M2) antibody (Sigma, St. Louis, MO) or 
anti-myc antibody (SC-40 HRP, Santa Cruz Biotechnology, Santa Cruz, CA). 
β-Galactosidase assays 
To evaluate the ability of each LexA+VP16 TAG mutant to activate transcription 
in the presence or absence of 1 mM pBpa, saturated cultures (SC media + 2% 
Raffinose ) of each mutant were used to inoculate 5 mL SC media containing 2% 
Raffinose + 2% Galactose but lacking histidine and tryptophan for selection. The 
cells were grown to an OD of 1.5-2.0 and harvested. The activity of each 
construct was monitored using β-galactosidase assays as previously described. 
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Chapter 3 Tandem reversible and irreversible crosslinking (TRIC) using 
genetically incorporated Bpa captures the direct interactions of DNA bound 
activators in S. cerevisiae. 
 
3.A.Summary3 
Methods for capturing protein-protein interactions (PPIs) in their native 
environment are critical for the construction of complete interaction maps of 
protein networks involved in such cellular processes as protein folding, signaling, 
and transcription. Often these networks rely on transient and moderate affinity 
interactions to execute their core function, historically the most difficult class of 
PPIs to isolate using traditional biochemical methods. Described herein is an 
approach for capturing PPIs in S. cerevisiae that employs the genetically 
incorporated photo-crosslinking amino acid p-benzoyl-L-phenylalanine (Bpa).  In 
these studies, Bpa is site-specifically incorporated in the transcriptional activation 
domain (TAD) of the activator VP16 using nonsense suppression technology 
optimized for use in yeast.  In vivo photocrosslinking with Bpa reveals a direct 
contact between VP16 and the general transcription factor TATA-binding protein 
(TBP).  To our knowledge, this is the first time a combinatorial crosslinking 
approach using tandem reversible formaldehyde crosslinking and irreversible 
                                                          
3
 This chapter is primarily comprised of data that is unpublished.  Contributions to the work in this 
chapter is as follows: Amanda Dugan was responsible for the experimental design and execution of 
experiments testing activator crosslinking to myc-TBP, endogenous TBP and initial TRIC data.  Rachel 
Pricer was responsible for obtaining a high-quality figure of the VP16-TBP TRIC interaction and she and 
Cassandra Joiner were additionally responsible for the execution of PCR experiments examining 
localization to the Gal1 promoter. 
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Bpa photo-crosslinking (TRIC) has been used to capture the direct interactions of 
DNA bound transcriptional activators in live yeast. This methodology is further 
used to identify TBP as a direct, cellular target of promoter bound VP16, thus 
resolving a nearly decade long debate over the relevance of this interaction. As 
such, TRIC can be used to capture direct interactions in a variety of PPI networks.  
3.B. Background 
Nearly every physiological process requires an intricately woven network of 
protein-protein interactions (PPIs) to dutifully carry out the executive orders of the 
cell.  Often these networks are replete with PPIs that vary greatly in interaction 
interface areas, affinities, and lifetimes.1  Illustrative of this complexity are 
transcriptional PPI networks whose key players, transcriptional activators, must 
recruit numerous multi-protein coactivator complexes in order to upregulate gene 
expression.2  In vivo co-localization and chromatin immunoprecipitation (ChIP) 
studies have been instrumental in identifying the complexes that are recruited by 
activators to the promoter, but the inherent limitations of these approaches have 
rendered them incapable of distinguishing the individual subunits within these 
complexes that serve as activator targets in vivo. For example, the formaldehyde 
used in ChIP experiments functions by non-specifically crosslinking protein-DNA 
and protein-protein interactions to covalently stabilize the complexes; however, 
because formaldehyde forms crosslinks with any nucleophilic side chains, this 
approach lacks the resolution to distinguish directly interacting subunits of 
complexes. Furthermore, affinity-based co-purification methods have proven to 
be poorly suited for studying transient PPIs, resulting in a plethora of conflicting 
reports that have hindered our understanding of the mechanisms surrounding 
coactivator recruitment at a given promoter.   
A relevant example of this struggle is the mechanism of recruitment of TBP to 
promoters by the activator VP16. As with other activators, VP16 uses its 
transcriptional activation domain (TAD) to initiate co-localization of numerous 
multi-protein complexes, including the Swi/Snf and SAGA chromatin remodeling 
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and modifying complexes, respectively, as well as Pol II and the associated 
holoenzyme3,4  One essential protein within the yeast holoenzyme, TBP, is 
recruited early on in transcription initiation and has been shown to localize to 
promoters in a VP16-dependent fashion.3,5,6 Data from in vitro biochemical 
studies suggest that this recruitment occurs through a direct interaction with TBP 
while in vivo localization data from Saccharomyces cerevisiae supports an 
indirect mechanism whereby TBP recruitment is mediated through the SAGA 
chromatin modifying complex.3,7-15  To resolve this and the many other 
outstanding questions surrounding the direct binding network of transcriptional 
activators, an alternative experimental strategy is needed.  
 
Studies in Chapter 2 demonstrated that in vivo photocrosslinking with the 
genetically incorporated unnatural amino acid p-benzyol-L-phenylalanine (Bpa) is 
a powerful tool to covalently capture the direct targets of transcriptional activators 
in live yeast, including transient and moderate affinity interactions that have 
historically proven the most difficult to study.  In this Chapter, implementation of 
the optimized incorporation system in yeast is used to site-specifically 
incorporate Bpa into the TAD of the activator VP16. Using in vivo photo-
crosslinking, the mechanism of recruitment of TBP by VP16, just one of many 
longstanding conflicts in the literature, is resolved.  Furthermore, the first 
example of the dual application of irreversible in vivo photocrosslinking and 
reversible formaldehyde crosslinking to isolate the direct interactions of promoter-
bound activators is described. This approach reveals important details regarding 
the actions of activators occurring at a specific promoter. 
3.C. The VP16-TBP interaction: the SAGA continues 
In yeast, TATA-binding protein (TBP) is a core component of the general 
transcription factor TFIID complex and it is essential for yeast viability and RNA 
Pol II-mediated transcription of protein-encoding genes.16,17  TFIID is one of the 
first general transcription factors to be recruited during transcription initiation. 
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During this process, the saddle-shaped TBP subunit of TFIID binds the minor 
groove of DNA, introducing a severe bend at the promoter and unwinding the 
double helix (Figure 3-1).18,19 DNA recognition by TBP is required for formation of 
the pre-initiation complex, which includes RNA polymerase II itself. The C-
terminal core domain of TBP is highly conserved among eukaryotes and in 
humans, and abnormal polyglutamine rich expansions in mutated TBP results in 
deregulated transcription and the onset of Spinocerebellar Ataxia-17, a 
Huntington-like neurological disorder.20  Given the essential nature of this protein, 
it is not surprising that the mechanism by which it is recruited to gene promoters 
has been the focus of innumerable studies over the last several decades (Figure 
3-1).  
 
Figure 3-1 TBP binding to DNA (PDB: 1YTB). Binding of Tata binding protein (TBP) to DNA is believed to be 
the rate-limiting first step in assembly of the pre-initiation complex (PIC) during transcription initiation.  As 
depicted here, binding of TBP to the minor groove of DNA induces a bend in the double helix, promoting the 
unwinding of DNA for RNA Polymerase II function. 
 
Studies with in vivo formaldehyde crosslinking have demonstrated TBP 
recruitment by VP16, but were unable to clarify whether this interaction occurs 
through a direct or indirect mechanism.3   One model has been proposed in 
which VP16 directly targets the concave DNA binding surface of TBP during 
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recruitment.  This model is substantiated by demonstrations that point mutations 
within the DNA binding surface of TBP abrogate VP16 binding in addition to 
evidence demonstrating the ability of VP16 to correctly orient TBP on the 
promoter.7,8   Because an activator-TBP complex has the potential to interfere 
with TBP binding to the TATA box, the nature of this particular interaction has 
been postulated to be transient in that it does not persist during PIC formation 
and function.  In addition to these studies, significant in vitro data exists to 
support a direct interaction between VP16 and TBP.9-12  Moreover, in line with 
previous biochemical data, in vitro crosslinking indicates that TBP has more than 
one binding site for VP16 as several different VP16-TBP crosslinked species 
were observed by Western blot.13 
Although there is strong support for a direct interaction model, several studies 
have proposed that the recruitment of TBP by VP16 occurs through a more 
indirect mechanism.  For example, one study suggests TBP recruitment occurs 
through activator interactions with TFIIB as VP16 is able to interact with a 
TFIID/A/B complex but unable to interact with a TFIID/A complex alone.15 
Another study suggests that the TBP/VP16 interaction is dependent on the 
SAGA subunit ADA2 after observing that GST-VP16 was unable to capture TBP 
from lysates lacking ADA2.21  Finally, a study from the Hahn lab demonstrated 
that deletion of the SAGA subunit Spt3 results in loss of TBP recruitment by 
VP16, also supporting an indirect model of recruitment.14    
 
 
Figure 3-2 The mechanism by which VP16 recruits TBP to the Gal1 promoter in yeast remains unclear.  
Several in vitro binding studies indicate that TBP is a putative target of VP16 in cells, but in vivo co-
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localization studies support a more indirect model of recruitment, one that is mediated through the SAGA 
chromatin modifying complex. 
3.C.1. Examining crosslinking of VP16 to myc-TBP in yeast 
 
Like many other transcriptional complexes, both SAGA and TFIID have been 
postulated to be combinatorially assembled in cells; therefore it is critical to 
examine the TBP-VP16 interaction in the native context where the full influence 
of complex subunit exchange can be considered.22,23  To determine if TBP is 
recruited through a direct interaction with VP16, in vivo photocrosslinking was 
carried out with a VP16 construct described in Chapter 2.  Briefly, a LexA+VP16-
FLAG plasmid was created by fusing the DNA binding domain of the bacterial 
repressor protein LexA to either the amino terminal subdomain of the VP16 TAD 
(412-456, VP16N) or carboxy terminal VP16 TAD (446-490, VP16C).  These 
plasmids were then transformed into a yeast strain bearing an integrated LacZ 
reporter gene under the control of a GAL1 promoter containing two LexA binding 
sites. Co-transformed along with the pLexA-VP16-flag plasmids was a plasmid 
for the Tyr tRNA/RS Bpa required for incorporation of Bpa at position 444 in 
VP16N and position 475 in VP16C.  Incorporation of Bpa at both positions tested 
showed an excellent incorporation and activity profile.  Therefore, these 





Figure 3-3 LexA+VP16-FLAG plasmids were created by fusing the DNA binding domain of the bacterial 
repressor protein LexA to either the amino terminal subdomain of the VP16 TAD (412-456, VP16N) or 
carboxy terminal VP16 TAD (446-490, VP16C).  These plasmids were transformed into a yeast strain 
bearing an integrated LacZ reporter gene under the control of a GAL1 promoter containing two LexA binding 
sites. Co-transformed along the pLexA-VP16-flag plasmids was a plasmid for the Tyr tRNA/RS Bpa required 
for incorporation of Bpa. A) Three positions in each subdomain of VP16 were tested for Bpa incorporation 
and transcriptional activity as measured by expression of the integrated LacZ reporter gene.  Given the 
excellent incorporation and activity of the LexA+VP16N L444Bpa and LexA+VP16C F475Bpa constructs 
were chosen for crosslinking experiments. 
 
Initial experiments were carried out with a myc-tagged TBP construct and 
LexA+VP16 L444Bpa or LexA+VP16C F475Bpa. Because C-terminal tagging of 
TBP impairs its function in yeast, the myc tag was placed on the amino terminus 
of the protein.24 Yeast cells expressing either VP16 construct and myc-TBP were 
then grown to mid-log phase and irradiated for 30 minutes with 365 nm UV light 
while kept on ice.  Post-irradiation, the yeast were lysed and their lysates 
immunoprecipitated with LexA antibody to precipitate all activator-containing 
complexes.  This mixture was then resolved and analyzed by Western blot with a 
myc-HRP antibody to detect the presence of a VP16-TBP interaction.   For both 
VP16 constructs tested, a covalent adduct with TBP was detected (Figure 3-4, 
top panel). Thus, in this experimental context, a direct interaction between VP16 
and TBP in living cells is occurring.  Further supporting these data, a point 
mutation was introduced into myc-TBP at a position shown in vitro to be critical 
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for binding to VP16 (L114K) and this mutation abrogated crosslinking of VP16 to 
TBP, indicating that the presence of Bpa in VP16 was not responsible for 
mediating the interaction.5  Furthermore, myc-TBP and myc-TBP L114K 
expressed at the same levels in yeast, thus the lack of crosslinking was not due 





Figure 3-4 (top) VP16 directly contacts myc-TBP in live yeast.  Yeast co-expressing LexA+VP16N L444Bpa 
or LexA+VP16C F475Bpa and myc-TBP were irradiated with UV light to activate Bpa and covalently capture 
interacting proteins.  After lysis, lysates were IP’d with a LexA antibody and the resulting Western blot was 
probed with an -myc antibody to detect a VP16-TBP interaction.  Introduction of a point mutation (L114K) in 
myc-TBP known to be important for TBP recruitment and binding by VP16 also abrogates crosslinking in 





To further define the interaction, Bpa was incorporated at residue 114 in myc-
TBP, a position previously shown to be critical in maintaining an interaction with 
VP16 in vitro, and crosslinking was carried out in cells co-expressing 
LexA+VP16N WT.  Consistent with earlier data, a covalently bound VP16-TBP 
complex was isolated from irradiated yeast (Figure 3-5). Thus, regardless of 
whether Bpa was incorporated in the activator or the recruited transcription factor, 
the VP16-TBP interaction was captured in living yeast.  
 
Figure 3-5 TBP crosslinks to LexA+VP16N WT and LexA+VP16C WT.  “Reverse” crosslinking was 
performed with Bpa containing TBP and wild-type constructs of VP16N and VP16C.  Yeast co-expressing 
myc-TBP L114Bpa and LexA+VP16N WT or LexA+VP16C WT were subjected to UV crosslinking and 
subsequently lysed.  Lysates were IP’d with an a-LexA antibody and the resulting Western was probed with 
an -myc antibody.  Placing the Bpa on the partner protein TBP results in the same outcome, with a 
covalent VP16-TBP adduct observed by Western blot.  
 
3.C.2. Crosslinking of VP16 to endogenous TBP  
Given the sensitivity of PPI networks to fluctuations in protein levels, specifically 
the overexpression of TBP in yeast, crosslinking of VP16 to endogenous TBP 
was next pursued.  First, a set of four antibodies were tested for their ability to 
immunoprecipitate free TBP from yeast lysate, and one antibody performed most 
consistently in these experiments.  With this in hand, live yeast co-expressing 
LexA+VP16N L444Bpa or LexA+VP16C F475Bpa and the Bpa tRNA/RS were 
irradiated with UV light and subsequently lysed.  Yeast lysates were 
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immunoprecipitated with TBP antibody followed by Western blot identification of 
TBP-VP16 covalent products using an -FLAG antibody.  Whereas a crosslinked 
product was readily observable for VP16 and myc-TBP, no observable 
crosslinked product was detected in these studies, even after several rounds of 
optimization.  As TBP is required for transcription by all three RNA polymerases, 
it is present in fairly high abundance in yeast cells (about 20,000 copies/cell).16  
However, the covalently bound VP16-TBP was at a low enough concentration to 
be outside the limits of the current detection capabilities.  According to Sigma, 
the manufacturer of the -Flag antibody used in these studies, increasing the 
number of Flag tags on the protein being investigated results in a 10- to 20- fold 
increase in detection capability of the antibody, thus allowing for the detection of 
low femtomolar quantities of protein.   After altering the Flag tag on VP16 to a 5x 
Flag epitope, crosslinking experiments were repeated and a direct contact 
between endogenous TBP and VP16 was observed (Figure 3-6, left panel, 60 
kDa).   Furthermore, when a double point mutation (L439P, F442P) was 
introduced into the VP16N TAD, crosslinking to TBP was abolished, indicating 
that this interaction is specific and not mediated by the presence of Bpa or the 
enhanced Flag tag (Figure 3-6, right panel).  Thus, in vivo photocrosslinking was 
able to capture a direct interaction with an endogenously expressed transcription 




Figure 3-6 VP16 crosslinks to endogenous TBP.  LexA+VP16N L444Bpa-5xflag and LexA+VP16C F475Bpa 
were transformed into yeast and cells were subjected to crosslinking under UV light.  After lysis, cell lysates 
were immunoprecipitated with an -TBP antibody and the subsequent Western blot was probed with an -
Flag antibody to detect a covalently bound TBP-VP16 complex.  (left blot) We found that both subdomains 
directly contacted TBP in cells, as determined by the presence of a band corresponding to the molecular 
weight of a TBP-VP16 product (60 kDa).  (right blot)  Introduction of a  double point mutation in the VP16N 
TAD known to impair VP16 activity and binding resulted in the abrogation of crosslinking to TBP in yeast.  
This data indicates that the addition of a 5xflag tag and the presence of Bpa within the TAD are not 
responsible for the formation of this interaction in yeast. 
3.D. TBP is a shared target of amphipathic activators in yeast 
As articulated in Chapters 1 and 2, amphipathic activators share little sequence 
homology yet have been suggested to share a common set of targets in the 
transcriptional machinery.25,26  In addition to VP16, several lines of evidence exist 
to support the recruitment of TBP to the GAL1 promoter by the yeast activator 
Gal4.  In the case of Gal4, the available literature suggests that TBP recruitment 
occurs through an indirect mechanism in which Gal4 recruits the SAGA complex 
and SAGA recruits TBP.  Several SAGA subunits have been shown to be 
required for both SAGA and TBP recruitment by Gal4.27  Of particular interest is 
the Spt3 subunit which has been shown to have no role in SAGA complex 
integrity but is believed to play a significant role in TBP recruitment.28-30 Genetic 
and biochemical studies have supported a Spt3p-TBP interaction and in vitro and 
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in vivo crosslinking studies were able to finally capture a direct interaction 
between Spt3 and TBP.14,31-33 Furthermore, deletion of Spt3 interferes with the 
recruitment of TBP but does not affect the promoter occupancy of SAGA or 
Gal4.30,34 Thus, other amphipathic activators were examined for their targeting of 
TBP in vivo, including the yeast activators Gal4 and Gcn4.  LexA+Gal4-5xflag 
and LexA+Gcn4-5xflag fusion proteins were expressed separately in yeast and 
subjected to in vivo crosslinking as described earlier.  Immunoprecipitation of the 
resulting cell lysates with TBP antibody followed by Western blot detection of the 
covalent complex with a -Flag antibody indicates that endogenous TBP is 
indeed a shared target of these three amphipathic activators, suggesting a 
common direct mechanism of recruitment of this essential yeast protein (Figure 
3-7).  
 
Figure 3-7 LexA+Gcn4 W120Bpa and LexA+Gal4 F869Bpa both crosslink to endogenous TBP in live yeast.  
After UV irradiation, yeast were harvested and the resulting lysates were immunoprecipitated with an -TBP 
antibody.  The following Western blot was probed with -Flag antibody to detect the presence of a covalently 
bound Gcn4 or Gal4.  In both activators, we were able to detect a direct interaction with endogenous TBP.  
3.E. Tandem reversible and irreversible crosslinking (TRIC) 
While in vivo photocrosslinking with Bpa is a powerful approach for capturing 
PPIs in their native environment, it is limited in its ability to differentiate the 
location and timing of the interaction, information that is critical to advancing our 
understanding of the mechanism of gene expression in vivo.  Thus, a method 
that affords the ability to examine direct activator interactions with these variables 





immunoprecipitation (ChIP) has come the closest to this goal, using 
formaldehyde chemical crosslinking to rapidly initiate protein-protein and protein-
DNA crosslinks in cells.  However, although researchers have used this 
approach for years to examine the complexes recruited to specific regions of the 
yeast genome, ChIP lacks the resolution to define the specific proteins within 
these recruited complexes that are engaging in direct interactions with 
transcriptional activators and other coactivator complexes during upregulation of 
gene expression. Given the utility of Bpa crosslinking in achieving this, the 
complementary approaches of reversible formaldehyde crosslinking and 
irreversible Bpa photo-crosslinking (TRIC) were combined to examine the direct 
interactions of DNA bound proteins.  In TRIC, cells are first crosslinked with 
formaldehyde which rapidly permeates the cell and reacts non-specifically with 
primary amines to covalently bind protein-DNA and protein-protein interactions.  
Formaldehyde crosslinked cells are then UV irradiated to activate the Bpa, thus 
forming site-specific covalent crosslinks with the direct binding partners of the 
activator within the immobilized complexes.  The chromatin of the cells is then 
isolated and washed to remove non-covalently bound protein and, following 
sonication, the DNA bound complexes can be immunoprecipitated.  Upon 
reversal of the formaldehyde crosslinks, only the interactions that were covalently 
captured with Bpa remain intact and these irreversibly crosslinked PPIs can be 
resolved on a Western blot, as before (Figure 3-8).   The work described herein 
demonstrates the utility of this methodology in building a comprehensive map of 
PPIs critical to the regulation of eukaryotic gene expression, further allowing for 
the examination of direct interactions in a promoter-specific context while also 
setting a foundation for the application of this approach in examining other 





Figure 3-8 Overview of TRIC. Briefly, cells are treated with formaldehyde to rapidly initiate protein-protein 
and protein-DNA crosslinks.  The formaldehyde reaction is then quenched and the cells are irradiated with 
UV light to activate the Bpa and capture directly interacting proteins within the formaldehyde crosslinked 
complex.  The chromatin fraction of the cells is then isolated, washed, and sonicated to shear and solubilize 
the chromatin.  Following immunoprecipitation, the formaldehyde crosslinks are reversed, leaving only the 
Bpa covalent irreversible products.  These covalent products can then be detected by Western blot, thus 
revealing the direct interactions of DNA bound activators. 
3.E.1. Capturing direct targets of DNA bound VP16 
Using the specific interaction between TBP and VP16 to test the TRIC method, 
we first transformed yeast with LexA+VP16N L444Bpa and the Tyr tRNA/RS 
required for Bpa incorporation.  Cells were harvested at mid-log phase OD660 
and then formaldehyde crosslinked for 20 minutes to establish protein-protein 
and protein-DNA crosslinks, essentially rendering these interactions immobilized 
in yeast.  Formaldehyde crosslinked cells were then irradiated under UV light for 
30 minutes on ice to activate Bpa and form irreversible covalent crosslinks 
between VP16 and TBP.  Upon cell lysis, the chromatin fraction of the cell was 
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isolated, washed to remove non-covalently bound proteins, and then sonicated to 
solubilize the chromatin. This soluble fraction was then immunoprecipitated with 
a TBP antibody and immobilized to a magnetic bead.  The formaldehyde 
crosslinks were reversed in elution buffer with boiling at 95 C, leaving only the 
irreversible Bpa crosslinks intact, and the immunoprecipitated proteins were then 
separated using SDS-PAGE. Any detectible VP16-TBP complex from the DNA 
fraction was then visualized on Western blot with an -FLAG antibody.    As 
expected, immunoprecipitation of yeast lysates yields a covalent adduct between 
VP16 and TBP in the presence of UV light as well as treatment with UV and 
formaldehyde.  However, when the chromatin fraction of the cells is isolated, a 
TBP-VP16 crosslink is only observed when formaldehyde was added to cells 
prior to UV irradiation (Figure 3-9).   Thus, this method confers a unique 
advantage in visualizing PPIs of DNA-bound proteins, exemplified here with a 
DNA-bound activator and an essential transcription factor.  
 
Figure 3-9 Tandem reversible and irreversible crosslinking captures the direct targets of DNA bound 
transcriptional activators.  Identical cultures of yeast expressing LexA+VP16N L444Bpa were either 
crosslinked under UV light for 30 minutes, formaldehyde crosslinked with 1% formaldehyde for 20 minutes, 
or treated with a combination of both procedures (formaldehyde followed by UV crosslinking).  Cell lysates 
were then immunoprecipitated per the standard protocol with an -TBP antibody and the samples were 
boiled for 20 minutes at 95*C to reverse the formaldehyde crosslinks, leaving only the irreversible Bpa 
crosslinked products intact.  The chromatin fractions of these cultures were washed to remove non-
covalently bound protein and then the chromatin was sheared and solubilized using sonication.  Soluble 
chromatin was then immunoprecipitated with an -TBP antibody and the formaldehyde crosslinks were 
reversed by boiling for 20 minutes, leaving only the irreversible Bpa crosslinked products intact.  The 
resulting Western blot of lysates and chromatin were probed with an -Flag antibody.  As expected from 
earlier experiments (Figure 6), we see a covalent VP16-TBP complex present in cell lysates from yeast 
irradiated with UV light.  For the chromatin fraction, the formaldehyde is required to stabilize DNA-protein 
interactions, so only in these samples do we immunoprecipitate protein from the chromatin fraction.  
However, upon reversal of the formaldehyde, only in the lane where Bpa was activated to form an 
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irreversible covalent bond do we see the VP16-TBP complex, indicating that this interaction occurs on DNA. 
Experiments done alongside Rachel Pricer. 
 
 
As mentioned previously, the yeast strain used in these studies carries an 
integrated LacZ reporter gene that is under the control of a Gal1 promoter that 
contains two LexA binding sites for our activator constructs.  Thus, TRIC 
experiments should report on interactions at this modified promoter.  To verify 
this method, the TRIC protocol was carried out again but this time the DNA was 
examined.  As a control, an aliquot of soluble chromatin was retained following 
sonication. Using primers designed to amplify the Gal1 promoter, PCR was 
carried out on the input as well as the DNA retained post-IP.  The PCR products 
were separated on an agarose gel and stained with ethidium bromide.  As shown 
in Figure 3-10, the input lanes all show the presence of the Gal1 promoter, as 
does a LS41 genomic DNA control.  However, only in conditions where 
formaldehyde is added to the culture is Gal1 amplified from the 
immunoprecipitated material (Figure 3-10).  Thus, the VP16-TBP interaction seen 
in Figure 3-9 is indeed bound to Gal1, as predicted. 
 
 
Figure 3-10 VP16-TBP interaction occurs at the Gal1 promoter.  The yeast strain used in these studies has 
an integrated LacZ reporter gene under the control of a Gal1 promoter that has two LexA binding sites. As 
such, the DNA bound interactions we observe for LexA+VP16N L444Bpa should only be occurring at this 
spot in the yeast genome.  To verify that this is the case, we carried out TRIC experiments in yeast, this time 
focusing only on the chromatin fraction.  Like before, chromatin was washed to remove non-covalently 
bound protein and then sonicated to shear and solubilize the chromatin.  For each condition tested, we 
saved an aliquot of solubilized chromatin as input for this experiment (pre-immunoprecipitation).  We then 
IP’d the chromatin with a TBP antibody followed by reversal of the formaldehyde crosslinks and digestion of 
protein and RNA with proteinase K and RNase I, respectively.  The remaining DNA and the input DNA was 
then subjected to PCR amplification with Gal1 promoter primers.  The Gal1 product is about 440 bps long, 
approximately the size of the product we see on the DNA gel above.  As expected, all input lanes and our 
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genomic DNA control show a large amplified band for Gal1, indicating its presence in the chromatin fraction.  
After immunoprecipitation, we only see the Gal1 DNA in conditions where formaldehyde was used to 
stabilize TBP and VP16 to the DNA, thus allowing us to IP it out (+F, -UV; +F+UV).  The leftmost lane 
contains a 1 kilobase ladder. 
 
3.F. Conclusion 
TBP is just one of many essential transcriptional proteins whose recruitment by 
activators is documented in a series of conflicting reports in the literature.  Using 
the long-contested VP16-TBP interaction as a model, we demonstrate that in 
vivo photocrosslinking is a valuable tool in clarifying the nature of the interactions 
that exist in transcriptional PPI networks, a feat that traditional methods were 
unable to accomplish.  This work led to the validation of TBP as a direct cellular 
binding partner of VP16 and additionally identified that this protein is a shared 
target with the activators Gal4 and Gcn4.  Further work will need to be carried out 
to determine if all three activators target the same region on TBP or if they 
differentially recruit TBP by contacting different surfaces, information that can be 
exploited when developing small molecules to specifically target this critical 
interaction.  
We furthermore demonstrate the utility of tandem reversible and irreversible 
crosslinking (TRIC) in capturing the in vivo direct interactions of DNA bound 
activators, an accomplishment that, to the best of our knowledge, has not been 
achieved up until this point.  This approach should reveal critical information 
about the mechanism of coactivator recruitment to DNA, thus yielding key 
insights to guide drug discovery efforts.  More broadly, this method should be 
useful in the capture and identification of other DNA bound PPIs, including 
histone modifying and remodeling enzymes and proteins involved in DNA repair 
pathways.  Additionally, this approach could even be used to look at the direct 
interactions within PPI networks localized to other areas of the cell including 
membrane PPIs as well as those occurring in the mitochondria, peroxisomes, 
and endoplasmic reticulum.  As the TRIC method becomes more refined, the 
inclusion of rapid mixing protocols that reduce formaldehyde crosslinking to a 
74 
 
shorter timescale should allow for the addition of a time scale in these 
experiments.  This would allow for changes in the activator-interaction profile 
during recruitment to be observed in a time-dependent fashion after induction, 
thus building a more complete picture of transcriptional interaction maps.   
 
3.G. Experimental 
Yeast Strain LS41 [JPY9::pZZ41, Mata  his3Δ200  leu2Δ1  trp1Δ63  ura3-52 
lys2Δ385  gal4 URA::pZZ41] was used for the crosslinking experiments.  Bpa 
was purchased from Chem-Impex International (Wood Dale, IL). All plasmids 
described below were constructed using standard molecular biology techniques. 
The sequences of all the isolated plasmids were verified by sequencing at the 
University of Michigan Core Facility (Ann Arbor, MI). 
Plasmid name Function 
 
pLexAVP16N WT Expresses LexA(1-
202)+VP16 (413-
456)+FLAG tag 










with a TAG 
replacing the 
codon of the 











with a TAG 
replacing the 
codon of the 
existing amino acid 
 
pLexAGcn4 120TAG 5xflag Expresses LexA(1-
202)+Gcn4(107-
144)+5xFLAG tag 
with a TAG codon 
replacing the 
codon of the 
existing amino acid 
pSNRtRNA-pBpaRS Expresses tRNA 
under the control 






pMyc TBP, pMyc TBP L114K, pMyc TBP 
L114Bpa 
Expresses full 
length TBP fused 
to c-myc tag on N 




3.G.1. Construction of plasmids 
1. pLexAVP16 N and pLexAVP16C 
A high copy plasmid expressing LexA(1-202)+VP16N (413-456)+FLAG tag and 
LexA(1-202)+VP16C (446-490))+FLAG tag under the control of the ADH1 
promoter was created from pCLexA containing EcoRI and BamHI sites.  Primers 




L114 with either a 
Lysine or TAG 
codon for Bpa 
incorporation 
pLexAVP16N 444TAG 5xFlag Expresses LexA(1-
202)+VP16(413-
456)+5xFLAG tag 
pLexAGal4 849TAG Expresses LexA(1-
202)+Gal4(840-
881)+FLAG tag 
with a TAG 
replacing the 
codon of the 
existing amino acid 





were used to amplify VP16 (413-456) using pMVP16 as a template.  The 
amplified PCR product was digested with EcoRI and BamHI and inserted into 
pCLexA digested with EcoRI and BamHI and treated with calf intestinal 
phosphate to create pLexAVP16N.   
Primers 5’ catgaattcATGTTGGGGGACGGG- 3’ and (5’-
catggatccTTACTTGTCATCGTCG -3’) were used to amplify VP16 (446-490) 
using pMVP16 as a template.  The amplified PCR product was digested with 
EcoRI and BamHI and inserted into pCLexA digested with EcoRI and BamHI and 
calf intestinal phosphate treated to create pLexAVP16C. 
 
2. pLexAVP16N 444TAG, pLexAVP16C 475TAG 
To create each plasmid, site-directed mutagenesis was used to replace an 
existing amino acid codon with TAG codon within the VP16C or VP16N TAD. In 
general, PCR primers were designed to have ~15 bases of homology on either 
side of the TAG mutation. QuikChange (Stratagene, La Jolla, CA) was used to 
incorporate the TAG mutants using manufacturer recommended conditions. 
3. pLexAGcn4(107-144) 
In a similar fashion to the VP16 plasmid construction, a high copy plasmid 
expression LexA(1-202)+Gcn4(107-144)+FLAG tag under the control of the 
ADH1 promoter was created from pCLexA containing EcoRI and BamHI sites. 
Primers 5’-GAATTCATGTTTGAGTATGAAAACCTAGAAGACAACTC-3’ and 5’-
GGATCCGGATTCA ATTGCCTTATCAGCCAATG-3’ were used to amplify 
Gcn4(107-144) from yeast genomic DNA.  The amplified product was digested 
with BamHI and EcoRI and then treated with Calf intestinal phosphatase to 
create pLexAGcn4. 
4. pLexAGal4 (840-881) 
pLexA(1-202)+Gal4(840-881) was created as previously described (Majmudar, 
CY et al, 2009) 
5. pGADT7 myc-TBP 
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A high copy plasmid pGADT7-myc expressing TBP under the ADH1 promoter, N-
terminally tagged with the c-Myc epitope was constructed by amplifying the DNA 
sequence encoding Med15(1-415) from yeast genomic DNA using primers (5’- 
catCATATGATGGCCGATGAGGAACGTTTAAAGG-3’) and (5’- 
atgCTCGAGTCACATTTTTCTAAATTCACTTAGC -3’) and inserted into NdeI and 
XhoI digested pMyc using standard molecular biology techniques. The pMyc 
cloning vector was created by inserting an ADH1 driven c-myc epitope tag in 
pGADT7 (Clontech) followed by restriction sites for gene insertion using site-






3.G.2. Incorporation of pBpa into LexA(1-202)+VP16N and LexA(1-202)+VP16C 
and expression of myc-TBP in S. cerevisiae pellet 
LS41 yeast was transformed with various pLexAVP16 TAG mutant plasmids and 
pSNRtRNA-pBpaRS plasmid. Individual colonies were grown to saturation in 5 
mL SC media lacking histidine and tryptophan for selection and 2% Raffinose at 
30 °C, with agitation.  Starter cultures were then used to inoculate 5 mL SC 
media lacking histidine and tryptophan, containing 2% Raffinose and 2% 
Galactose. For pBpa incorporation, 50 L of 100 mM pBpa dissolved in 1M 
NaOH and 50 L 1M HCl were added to the above cultures.  The cultures were 
grown overnight at 30 °C, with agitation to an OD660 of ~1.0. 3 OD’s of cells were 
harvested and the cell pellets were lysed in 12 uL pellet lysis buffer (50 mM Tris 
Acetate, pH 7.9, 150 mM KOAc, 20% glycerol, 0.2% Tween-20, 2 mM MgOAc) 
containing complete EDTA free protease inhibitor tablets (Roche), 7 uL 1 mM 
DTT, and 7 uL 4X LDS NuPAGE dye (Invitrogen).  Lysates were boiled at 95 °C 
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and analyzed using Western blot with anti-FLAG (M2) antibody (Sigma).  To test 
expression of the myc-TBP construct, the same protocol was followed except 
that LS41 were additionally transformed with the pGADT7-mycTBP plasmid and 
grown in SC media lacking histidine, tryptophan and leucine.  Lysates were 
analyzed using Western blot with anti-myc antibody (Santa Cruz Biotech, sc-40). 
3.G.3. In vivo cross-linking 
To perform in vivo cross-linking, individual colonies of each pLexAVP16 TAG 
mutant were grown in 5 mL SC media containing 2% Raffinose but lacking 
histidine and tryptophan for selection. The cultures were incubated overnight at 
30 °C with agitation. Following incubation, these cultures were used to inoculate 
100 mL cultures of SC media containing 2% Raffinose and 2% Galactose. For 
pBpa incorporation, 1 mL 100 mM pBpa dissolved in 1M NaOH and 1 mL 1M HCl 
were added to the above cultures. The cultures were incubated overnight at 
30 °C with agitation to an OD660 of ~1.0. When cultures reached the appropriate 
OD660, the cells were spun down by centrifuging at 3901 rcf at 4
oC for 5 min. 
following which the cell pellets were washed with SC media lacking histidine and 
tryptophan.  The cell pellets were resuspended in 2mL SC media lacking 
histidine and tryptophan + 2% Raffinose, 2% Galactose and transferred to small 
cell culture dishes and subjected to UV irradiation at 365 nm light (Eurosolar 15 
W UV lamp) with cooling for 0.5 h. The cells were isolated by centrifugation and 
stored at -80oC until lysis.   
For crosslinking studies with mycTBP, the procedure was identical except that 
cells were grown in SC media lacking histidine, leucine, and tryptophan.  For 
lysis, cells were resuspended in 600 μL Lysis buffer (50 mM HEPES-KOH pH 7.5, 
140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-Deoxycholate and 2X 
Complete Mini, EDTA Free Protease Inhibitor (Roche) and lysed using glass 
beads by vortexing at 4 °C. Subsequently, the lysate was pelleted and the 
supernatant incubated with 10 μL of LexA antibody (sc-1725, Santa Cruz 
Biotechnologies) for 2 h at 4 °C for immunoprecipitation. The protein bound to the 
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antibody was isolated by incubation for 1 h with either ~50 μL of prewashed 
protein G magnetic beads (Dynal Corporation, Invitrogen, Carlsbad, CA) or ~ 8 
uL prewashed protein G agarose beads (Millipore) at 4 oC. After 
immunoprecipitation, the beads were washed 6 times with 1 mL Wash Buffer (10 
mM Tris-HCl pH 8.0, 250 mM LiCl, 0.5% NP-40, 0.1% Na-Deoxycholate and 1 
mM EDTA) and stored dry at -80 oC until elution. The crosslinked sample was 
eluted from the beads by heating at 95 oC for 10 min in NuPAGE 4x LDS Sample 
buffer (Invitrogen, Carlsbad, CA) containing 250 mM DTT and probed using 
Western Blot analysis using anti-FLAG (M2) antibody (Sigma, St. Louis, MO) or 
anti-myc antibody (SC-40 HRP, Santa Cruz Biotechnology, Santa Cruz, CA). 
3.G.4. β-Galactosidase assays 
To evaluate the ability of each LexA+VP16 TAG mutant to activate transcription 
in the presence or absence of 1 mM pBpa, saturated cultures (SC media + 2% 
Raffinose ) of each mutant were used to inoculate 5 mL SC media containing 2% 
Raffinose + 2% Galactose but lacking histidine and tryptophan for selection. The 
cells were grown to an OD of 1.5-2.0 and harvested. The activity of each 
construct was monitored using β-galactosidase assays as previously described 
(Majmudar, C.Y. et al 2009). 
3.G.5. Tandem reversible and irreversible crosslinking 
To perform TRIC, individual colonies of each pLexAVP16 TAG mutant were 
grown in 5 mL SC media containing 2% Raffinose but lacking histidine and 
tryptophan for selection. The cultures were incubated overnight at 30 °C with 
agitation. Following incubation, these cultures were used to inoculate 100 mL 
cultures of SC media containing 2% Raffinose and 2% Galactose. For pBpa 
incorporation, 1 mL 100 mM pBpa dissolved in 1M NaOH and 1 mL 1M HCl were 
added to the above cultures. The cultures were incubated overnight at 30 °C with 
agitation to an OD660 of ~1.0. When cultures reached the appropriate OD660, the 
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cells were spun down by centrifuging at 3901 rcf at 4oC for 5 min. following which 
the cell pellets were washed with SC media lacking histidine and tryptophan.   
The cell pellets only receiving UV treatment were resuspended in 2mL SC media 
lacking histidine and tryptophan + 2% Raffinose, 2% Galactose and transferred 
to small cell culture dishes and subjected to UV irradiation at 365 nm light 
(Eurosolar 15 W UV lamp) with cooling for 0.5 h.  
The cell pellets receiving formaldehyde treatment were resuspended in 1 mL DI 
water and added to a 100 mL solution of 1% formaldehyde in water (2.7 mL of 
37% formaldehyde solution into 97.3 mL water).  Cells were crosslinked with 
formaldehyde for 20 minutes before being quenched with 30 mL of 2M Glycine.  
Cells were then centrifuged and washed with 50 mL DI water.  Samples intended 
to additionally receive UV crosslinking were resuspended in 2 mL SC media 
lacking histidine and tryptophan +2% Raffinose, 2% Galactose and transferred to 
a small cell culture dish and subjected to UV irradiation at 365 nm UV light 
(Eurosolar 15 W UV lamp with cooling for 0.5h. 
For lysis, cells were resuspended in 600 μL Lysis buffer (50 mM HEPES-KOH pH 
7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-Deoxycholate and 
2X Complete Mini, EDTA Free Protease Inhibitor (Roche) and lysed using glass 
beads by vortexing for 45 minutes at 4 °C.  We found in these studies that 
complete cellular lysis is necessary to eliminate background signal caused by cell 
lysis during sonication. Subsequent lysates  were immunoprecipitated with 8 uL 
TBP antibody (santa cruz, sc-33736) and incubated for 2 hours at 4 deg C.  The 
remaining pellet is then washed 4x with “Harsh” ChIP buffer (50 mM HEPES-
KOH pH 7.5, 1M NaCl, 1 mM EDTA, 1% Triton X-100, 1% Na-Deoxycholate)  
followed by 2 washes with regular ChIP buffer (50 mM HEPES-KOH pH 7.5, 140 
mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-Deoxycholate and 2X 
Complete Mini, EDTA Free Protease Inhibitor (Roche)). Pellets were 
resuspended in 600 µL ChIP lysis buffer containing protease inhibitor and 
sonicate at a setting of 10% (3 on Marsh lab sonicator, Fisher Scientific) for 2 
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minutes with 30 sec pulse on/off.  Samples were then centrifuged in the cold 
room for 20 minutes at max speed.  Soluble chromatin was then removed from 
the pellet and immunoprecipitated with TBP antibody (santa cruz, sc-33736) for 2 
hours, 4 deg C. The protein bound to the antibody was isolated by incubation for 
1 h with either ~50 μL of prewashed protein G magnetic beads (Dynal 
Corporation, Invitrogen, Carlsbad, CA) or ~ 8 uL prewashed protein G agarose 
beads (Millipore) at 4 oC. After immunoprecipitation, the beads were washed 6 
times with 1 mL Wash Buffer (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 0.5% NP-40, 
0.1% Na-Deoxycholate and 1 mM EDTA) and stored dry at -80 oC until elution. 
The crosslinked sample was eluted from the beads and formaldehyde crosslinks 
reversed by heating at 95 oC for 20 min in NuPAGE 4x LDS Sample buffer 
(Invitrogen, Carlsbad, CA) containing 250 mM DTT and probed using Western 
Blot analysis using anti-FLAG (M2) antibody (Sigma, St. Louis, MO). 
 
For studies examining the DNA IP’d during TRIC, the TRIC protocol was followed 
with the exception of 50 uL of solubilized chromatin being saved prior to 
immunoprecipitation.  Additionally, lysates were discarded in these experiments.   
 
To examine the size of the sheared chromatin, 50 µL TE/SDS was added to the 
Input samples and incubated overnight at 65°C to reverse crosslinks. 2.5 µL 
proteinase K (20 mg/mL stock) was then added and incubated at 50°C for 3 
hours to digest proteins, followed by a PCR cleanup. 0.5 µL RNAse A (1 mg/mL 
stock) was added and then incubated at 37°C for 30 min. samples were 
visualized on 1% agarose gel.  Smear should show between 300-600 bps.   
 
For PCR on TRIC samples, 90 µL TE/SDS was added to 50 uL input and 
incubated overnight at 65°C followed by PCR Cleanup and elution in 58 µL EB 
buffer.  DNA is then measured and PCR set up (See table). For Chromatin, 
beads were washed 2x with lysis buffer, 1 time with 500 mM NaCl lysis buffer, 1 
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time with wash buffer, and 1 time with TE buffer (10 mM Tris-HCl, 1 mM EDTA, 
0.01% SDS (5 g in 500 mL ex) 
. 50 µL elution buffer(50 mM Tris-HCl, 10 mM EDTA, 1% SDS) was then added 
to the beads and vortexed briefly before incubating at 65°C for 30 minutes, with 
vortexing every 5 minutes to resuspend the beads.  Beads were centrifuged for 
30 sec at 3000 rpm and  the eluent transfered to a new tube. 120 µL TE/SDS 
was added and incubated overnight at 65°C followed by a PCR cleanup, elution 
in 58 µL EB buffer.  Measure DNA on nanodrop and set up PCR (See table). 
Products were visualized on a 1% agarose gel stained with ethidium bromide.   
 
For 25 µL Final PCR Volume 
2.5 µL 10x Pfu buffer 
0.5 µL 10 mM DTNPs 
0.5 µL each primer 
0.5 µL Pfu Turbo 
2.0 µL template DNA 
17.5 µL water 
1 µL 50 mM MgCl2 
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Chapter 4 Identification of novel targets of transcriptional activators using in vivo 
photocrosslinking and mass spectrometry 
 
4.A.Background4 
Fundamental to the regulation of eukaryotic gene expression are transcriptional 
activators, a family of signal responsive proteins that recruit numerous 
coactivator complexes to the promoter of a gene and assemble the requisite pre-
initiation complex (PIC).  Regarding these complexes, much effort has been put 
forth over the past several decades to construct an interaction map detailing the 
individual protein subunits that serve as the direct binding partners of activators 
in vivo.  Biochemical studies have been able to contribute a modest amount of 
useful information toward this goal; however, in many cases the approaches 
used have been poorly-suited to accommodate the discovery of activator targets 
in a high-throughput fashion.  Recently, mass spectrometric methods for the 
analysis of complex protein mixtures have been hailed as a superior route for the 
discovery of activator interactions. Indeed, several publications in recent years 
have employed this strategy to examine activator recruitment in vitro, with 
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particular focus on well-characterized Pol II holoenzyme and coactivator 
complexes.1,2  While this work has garnered a deepened appreciation of the 
complexities surrounding pre-initiation complex assembly, such a powerful 
platform has yet to be employed to investigate activator recruitment beyond the 
core set of classical targets.  Moving forward, we chose to combine mass 
spectrometry with in vivo photocrosslinking to discover new, direct targets of the 
prototypical yeast transcriptional activator Gal4.  These studies resulted in the 
capture of several previously unidentified targets of Gal4, a subset of them being 
in the Snf1 kinase complex, which shares significant homology with the human 
AMPK complex, a leading drug target candidate for the regulation of type II 
diabetes. 
 
Transcriptional activators are modular proteins, possessing a DNA binding 
domain (DBD) that recognizes cognate sequences within the promoter and a 
transcriptional activation domain (TAD) that mediates the contacts required for 
recruitment of transcriptional complexes.  The associations that an activator 
makes with a single TAD are numerous and can vary greatly in affinity, ranging 
from low nanomolar interactions with masking proteins to more moderate affinity 
interactions with coactivator complexes.  One particularly well-characterized 
system includes the yeast activator Gal4, whose activity is regulated by changes 
in carbon source availability. In the presence of glucose, Gal4 is tightly repressed 
by its masking protein Gal80; however, in the presence of galactose, an inducing 
sugar, repression of Gal4 is relieved, leaving Gal4 free to interact with complexes 
involved in galactose sensing and catabolism.3-5  Historically, investigations of 
Gal4 have utilized this switch-like activation to examine the mechanism of 
transcriptional regulation by Gal4, focusing primarily on the interactions with 
Gal80 and classical transcriptional complexes including SAGA, Swi/Snf, Mediator 
and other components of the Pol II holoenzyme.3-18  However, little has been 
done in the way of establishing a map of Gal4 PPIs outside the previously 
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identified associations with the core transcriptional machinery.   This is primarily 
due to the dearth of methods available to capture a broad range of PPIs in the 
native cellular environment combined with a limited number of approaches 
available to analyze complex protein mixtures, particularly those of low-
abundance.  Methods that additionally allow for protein identification in a high-
throughput fashion would facilitate activator PPI discovery.  In order to achieve 
the longstanding goal of building a complete interaction map for transcriptional 
networks, new approaches, or a combination of approaches, must be utilized. 
4.B. Toward activator interaction discovery  
As demonstrated in Chapters 2 and 3, photocrosslinking with genetically 
incorporated amino acids affords the ability to capture both stable, high affinity as 
well as transient and moderate affinity PPIs in their native cellular 
environment.8,10  Briefly, this method relies on an evolved tRNA/tRNA synthetase 
(RS) pair that work to site-selectively incorporate the photocrosslinking unnatural 
amino acid (UAA) in response to an amber (UAG) stop codon in the mRNA being 
translated.19,20   Work from our group and others has implemented this 
technology in yeast to incorporate the photo-labile UAA p-benzoyl-L-
phenylalanine (Bpa) to capture transcriptional PPIs, notably those between 
coactivator complexes as well as activator-coactivator interactions.8,10,21  
Investigations with the yeast activator Gal4 demonstrated that Bpa incorporation 
along the Gal4 TAD occurs with minimal impact on activator binding and function.  
Furthermore, subsequent crosslinking of these Gal4 constructs in yeast indicated 
that, as expected, each position tested yielded a multi-protein binding profile, with 
position 849 appearing to capture protein partners with high efficiency relative to 
the other positions tested. (Figure 4-1). Since these initial experiments, the 
identities of these crosslinked complexes have been examined in detail using 
classical immunodetection techniques, finding important targets within the 
transcriptional machinery including the Mediator protein Med15, the TATA-
associated factor Taf12, the Swi/Snf ATPase Snf2, and the SAGA subunit Tra1, 
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among others.510  However, while these studies were important in filling in pieces 
of the activator-coactivator puzzle, this hypothesis driven approach is neither 
suitable nor practical for discovery mode identification of activator binding 
partners.  Therefore, there is a clear need to access a more high-throughput and 
unbiased route to discover the identity of the many crosslinked partners that exist.   
 
Figure 4-1 .  Gal4 exhibits a multiprotein binding profile for each position within the Gal4 TAD incorporating 
Bpa.  Yeast expressing the various Gal4 Bpa mutants were crosslinked under UV light to capture the direct 
binding partners of Gal4 in live cells.  The covalent adducts were immunoprecipitated with an -LexA 
antibody and probed with an -Flag antibody
8
.  LexA+Gal4 F849Bpa (highlighted by red square) was 
selected for MS analysis given its robust crosslinking profile. 
4.B.1. Multi-dimensional protein identification technology (MuDPIT) to analyze 
complex protein mixtures 
The mass spectrometry based approach multi-dimensional protein identification 
technology (MuDPIT), offers several advantages for the discovery of novel 
interaction partners. First, mass spectrometry is the most sensitive technique that 
enables discovery of novel targets with no prior information required for target 
identification. Further, the MuDPIT strategy is designed to effectively separate 
and analyze complex protein mixtures, thus providing added resolution and 
sensitivity over other traditional in gel digestion MS approaches, and it has 
already been used successfully in proteomics studies in S. cerevisiae.  MudPIT 
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 Gal4 crosslinking in vivo to Taf12 and Tra1 is unpublished data, A.Nwokoye, Y-H. Fung, and C.Y. Majmudar 
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was first described by the Yates lab where it was used to examine the proteome 
of yeast, proving sensitive enough to detect membrane proteins and low-
abundance transcription factors.22,23  Whereas traditional proteomics approaches 
require protein mixtures to first be separated by 2-dimensional electrophoresis 
and then isolated manually by excising and digesting specific bands from the gel, 
MudPIT eliminates the need for cumbersome in-gel techniques by digesting the 
protein mixture directly and then separating the resulting peptides using a high 
resolution 2D liquid chromatography approach. This entails sample peptides first 
separated on a strong cation exchange (SCX) column followed by reverse phase 
(RPLC) chromatographic separation to achieve maximum resolution of peptide 
species.  As the peptides are eluted off the chromatography column, they are 
automatically injected into the mass spectrophotometer for tandem MS (MS/MS) 
analysis.  During MS/MS runs, the masses of the digested peptides are first 
measured before being fragmented further using collision-induced dissociation, 
followed by measurement of the masses of the fragmentation products.24   
Due to the enormous amount of data this method generates, powerful 
computational programs are used to assign amino acid sequences and relative 
abundance of each peptide.  Historically, MS-based approaches have 
demonstrated excellent sequence coverage for only the most abundant peptides 
in a given sample.  However, advocates of MudPIT suggest that this method is 
sensitive enough to identify even a single peptide in a complex mixture, thereby 
conferring an advantage over in-gel techniques that would fail to detect such a 
small quantity of protein.  Demonstrating the power of a variation of this approach, 
Shen and colleagues were able to use an enhanced RPLC-MS/MS technique to 
identify over 2000 proteins in human plasma whose abundance varied over six 
orders of magnitude.25  Given this sensitivity, MudPIT appears to offer the most 
straightforward route for identifying the complex mixture of binding partners of 
Gal4 captured in our crosslinking experiments and additionally be the most 
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powerful approach for analyzing transcriptional complexes that are notoriously 
low in abundance and often difficult to detect.  
 
Figure 4-2 Approaches for the identification of activator targets from in vivo photocrosslinking studies.  Live 
yeast expressing Bpa containing transcriptional activators (blue and red) are irradiated with UV light to 
covalently capture the direct interactions of the activator with masking proteins (green), transcriptional 
machinery proteins (orange) and novel targets (grey).  Cells are then lysed and the covalent complexes can 
be immuno-purified out of cell lysates.  These purified products can then be identified via traditional 
immunodetection techniques such as Western blotting (top) or using mass spectrometric based methods 
which concurrently allow for the identification of novel binding partners. 
 
4.B.2. Inherent challenges of crosslinking-MS studies 
While the challenges facing a combinatorial crosslinking-MS approach have been 
well-documented, significant advancements have been made since the initial 
report of MudPIT, making this goal more feasible as more enhancements are 
introduced. 26-29  One particular challenge associated with studying transcriptional 
systems, for example, is the relatively low abundance of these proteins in cells, 
with some proteins as low as 50-100 copies/cell (compare with >200,000 
copies/cell for some ribosomal proteins).30  Although mass spectrometric 
approaches are often biased toward higher abundance proteins, researchers 
have found several ways to improve the sensitivity and signal of low abundance 
peptides, such as using longer, thinner capillaries to more efficiently separate 
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peptides during RPLC as well as using isotopically labeled proteins to increase 
the signal to noise ratio of these experiments (SILAC).31,32  As an additional 
measure, cryo-lysis procedure was incorporated to prevent the degradation of 
already low abundance transcriptional complexes.  In this approach, crosslinked 
cells are kept frozen with liquid nitrogen and lysed in a planetary ball mill at 
around -200 °C, a temperature low enough to severely reduce the activity of 
proteases that could interfere with these studies.  Importantly, a collaboration 
with Dr. Ben Cravatt, a leading expert in MS-based proteomics research and co-
director of the Center for Physiological Proteomics at the Scripps Research 
Institute, was established.  
 
4.C. Combining in vivo photo-crosslinking and MuDPIT to identify novel binding 
partners of Gal4 in yeast 
To date, the analysis of activator interactions using MudPIT has been mostly 
limited to experiments examining the in vitro assembly of well-studied 
transcriptional components on naked DNA and chromatinized templates.  As 
discussed in previous chapters, this in vitro examination of transcriptional 
assembly does not necessarily correlate to transcriptional events that occur at 
the promoter in vivo.  Therefore, in this chapter, we chose to examine activator 
interactions in live yeast using in vivo photocrosslinking and use the full power of 
MudPIT to identify novel targets of Gal4 rather than focusing on previously 
identified transcriptional partners.  The advantage of this combined approach is 
that the activator PPI network is kept in its native environment, allowing for the 
effects of factors such as cellular localization, nuclear membrane proteins, post-
translational modifying enzymes, ubiquitin ligases, and proteosome components 
to be considered, as all of these have been shown to be important for regulating 
activator function.33-40 Thus, the use of Bpa crosslinking in live yeast combined 
with MS analysis should yield significantly more information regarding the full 
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spectrum of interactions that activators directly engage in during transcription 
(Figure 4-2).  
4.C.1. Proof of principle: identification of crosslinked Gal4-Gal80 using MudPIT 
  As an initial experiment to test the feasibility of this approach, Drs. Majmudar 
and Lancia first examined if the protocol was robust enough to capture the well-
characterized Gal4-Gal80 interaction.  These studies utilized a LexA+Gal4 
F849Bpa-1xflag-6His construct whose two C-terminal tags could be used as 
purification handles to obtain a clean sample for MS analysis.  The sensitivity of 
this construct to Gal80 repression under glucose conditions was examined as 
well as its ability to upregulate transcription of the integrated LacZ reporter gene 
in our yeast strain under inducing galactose conditions, as described in Chapter 
2.  As shown in Figure 4-3 lower left panel, LexA+Gal4 F849Bpa-1xflag-6His was 
indeed activated in galactose and repressed in glucose, indicating that this 
construct is interacting with Gal80 in the conditions of the experiment.   
Next, to examine the Gal4-Gal80 interaction with MuDPIT, experiments were 
scaled up to 1 L cultures of yeast transformed with a LexA+Gal4 F849Bpa-
1xflag-6His construct and the tRNA/RS required for Bpa incorporation.  Yeast 
cells were grown in glucose (i.e. conditions that promote repression of Gal4 by 
Gal80) and then UV-irradiated for 30 minutes on ice.  As a control, a batch of 
cells was also grown in galactose which should relieve repression by Gal80 and 
theoretically result in a reduced observation of this interaction via MS studies.  
Each batch of cells was lysed using the specialized cryo-lysis procedure and the 
crosslinked Gal4 products were purified from yeast lysate using an optimized 
tandem purification strategy designed to reduce false positives.  This purification 
protocol takes advantage of the fact that the activator is covalently crosslinked to 
its binding partners, thus allowing stringent purification conditions to be used 
without any concern of disrupting the activator interactions.  Briefly, covalent 
products were bound to nickel agarose to capture the 6xHis tag on Gal4 and then 
stringently washed under denaturing conditions to eliminate non-specific 
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hydrophobic interactions.  Following elution off the nickel agarose, the partially 
purified adducts were added to agarose conjugated with -Flag antibody to 
capture the Flag tag on the covalently crosslinked activator products. 
Subsequently, the bound Gal4 products are eluted off the Flag-agarose through 
competition with a flag peptide, a mild elution option that leaves unwanted protein 
bound to the -flag agarose.  Finally, the purified products are buffer exchanged 
into a MS compatible ammonium bicarbonate buffer, allowing for the 
simultaneous removal of excess flag peptide, before being trypsin digested, 
frozen, and sent to Dr. Sherry Niessen at the Center for Physiological Proteomics 
for MuDPIT analysis (Figure 4-3 top panel).  As shown in Figure 4-3 lower right 
panel, capture of the Gal4-Gal80 interaction was indeed observable by MuDPIT 
analysis and, furthermore, this interaction was observed to be five times more 
abundant under glucose conditions than in galactose.  The presence of Gal80 in 
the galactose sample is not completely surprising as it has been suggested that 
Gal80 does not necessarily dissociate from Gal4 during derepression of 
galactose inducible genes.41,42  Together, this data indicates that our 
experimental setup is transcriptionally responsive in yeast and that Bpa 
crosslinking and MuDPIT should serve as a reliable platform upon which to 
examine activator PPIs in vivo. 
4.C.2. Using in vivo photocrosslinking and MuDPIT to capture and identify Gal4 
PPIs 
 Original experiments with the Gal4 TAD (Figure 4-1) tested several sites 
of incorporation for Bpa, resulting in the finding that Bpa incorporation and 
crosslinking efficiency is significantly influenced by the positional context of the 
crosslinking moiety within the protein domain.8   Furthermore, given the low 
abundance of transcription factors, it was critical to use a Gal4 construct that 
showed a robust and repeatable crosslinking profile as this will enhance the 
capture of these minimally available proteins in cells.  As such,  LexA+Gal4 
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F849Bpa was chosen as the focus of future experiments as this position displays 
an intense crosslinking profile and should provide a better sample signal during 
MS analysis.   While additional efforts to increase sample signal were attempted 
by isotopically labeling yeast cultures with either 15N-labeled ammonium sulfate 
or 13C, 15N labeled Lysine and Leucine (SILAC), this optimization effort proved 
unsuccessful in our hands. As a result of low levels of incorporation of the 
isotopically labeled amino acids, this strategy was not pursued further.  
Because the initial MuDPIT analysis of Gal4 crosslinked products from 1L 
cultures showed low signal to noise for many transcription factors, the reaction 
conditions of these experiments was scaled up by expressing 10-15 L of yeast in 
an effort to boost the signal of crosslinked peptides.  Yeast were harvested at 
mid-log phase growth and irradiated with UV light for 30 minutes with cooling 
before freezing the cells and subjecting them to lysis using the cryogenic 
planetary ball mill.  Following purification, samples were sent for analysis.  A 
selected summary of results are summarized in Table 4-1. The proteins listed 
were selected based on a minimum number of 5 spectral counts, at least 5 fold 
enrichment in +UV conditions over –UV conditions, and the cellular abundance 





Figure 4-3. Gal4 directly targets Gal80 as identified by a combined in vivo photocrossking and MuDPIT 
approach.(top panel) A 1L yeast culture grown in glucoses was irradiated with UV light to form covalent 
adducts between LexA+Gal4 F849Bpa-6HIS-flag and its binding partners under repressive conditions.  Cells 
were then lysed using a procedure that uses liquid nitrogen to keep cells frozen during lysis, thus reducing 
the activity of proteases.  Using a tandem purification protocol, the lysates are then incubated with nickel 
agarose to affinity purify the 6HIS tag on Gal4, followed by incubation with Flag-agarose to 
immunoprecipitated out the flag tagged activator-adducts.  Purified complexed proteins were then digested 
and submitted to Dr. Sherry Niessen for MuDPIT analysis.   (Bottom Left) -galactosidase activity assays 
indicate that LexA+Gal4 F849Bpa 6HIS-flag is sensitive to transcriptional repression in the presence of 
Glucose and can be activated in the presence of the inducing sugar Galactose. (Bottom Right) MuDPIT 
analysis correlates with activity data in that Gal80 binding is enriched under repressive glucose conditions 











 Table 4-1 Novel targets of Gal4 captured through in vivo photocrosslinking 
and MuDPIT identification.    
 
 
 Crosslinking-MS studies revealed several previously unidentified targets 
belonging to complexes that have some precedence in influencing transcription 
including proteasome proteins (Blm10), membrane-bound kinases (Kc11), 
exportin proteins (XpoI), and cell cycle arrest proteins (Far8) as well as protein 
targets whose functional relevance is more abstract, including tRNA 
methytransferases (Trm82) and mitochondrial proteins(Mam3).  Of the targets 
identified in this analysis, two of particular note belong to the Snf1 kinase 
complex, a key regulatory complex involved in glucose/galactose sensing and 
catabolism.  Although both Gal4 and Snf1 have been implicated in regulating 
galactose inducible genes, little evidence exists to support an interaction in vitro 
and, to our knowledge, no data exists to support this interaction in cells.43   These 
data suggest that a key player in galactose catabolism has been left largely 
overlooked in studies involving Gal4; thus, subsequent validation efforts were 
focused upon these interactions. 
4.D. The Snf1 complex in galactose catabolism 
In the response to stressors such as glucose depletion, the Snf1 kinase complex 
plays a critical role in regulating metabolic response where it is essential for 
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transcription of genes involved in gluconeogenesis and galactose catabolism.  
This complex is heterotrimeric in composition, containing a catalytic alpha 
subunit (Snf1), a regulatory gamma subunit (Snf4), and a third beta subunit that 
exchanges between Sip1, Sip2, and Gal83 to regulate subcellular localization of 
the complex.44 The Snf1 complex is believed to function in glucose repression 
and galactose activation pathways by acting on the Mig1 repressor, a DNA 
binding protein shown to localize to genes regulated by Gal4.  Under conditions 
of high glucose, Snf1 is inactivated and remains largely localized in the 
cytoplasm, leaving Mig1 to localize to the nucleus and recruit the Cyc8-Tup1 
complex to DNA to inhibit transcription.  In contrast, when glucose is depleted 
and galactose is introduced, Snf1 becomes activated and localizes to the nucleus 
where it is believed to phosphorylate Mig1 and induce its export to the cytoplasm, 
thus allowing transcription to occur (Figure 4-4).45-48   Additional evidence 
suggests that the Snf1 complex interacts with components of the Mediator 
complex to increase activity of the Pol II holoenzyme.49   Thus, significant 
evidence exists to support an important role of the Snf1 kinase complex in 
upregulating transcription of galactose inducible genes.  However, while several 
studies have examined the interaction of this complex with other activators, no 
studies have been performed to examine how this complex is recruited to 
promoters controlled by Gal4, such as the GAL1 promoter used in these 
investigations.  Thus, a significant aspect regarding how Gal4 regulates 
expression of galactose inducible genes remains unexplored. 
 
 
Figure 4-4 The Snf1 kinase complex has been shown to be critical during stress response to low glucose. 
Under conditions of high glucose, the complex is inactivated and cytoplasmic but shuttles to the nucleus 
under activating conditions of low glucose.  Snf1 complex has implicated as important to transcription of 
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galactose inducible promoters including the GAL1 promoter used in our studies and data supports a role of 
this complex in phosphorylating the transcriptional repressor Mig1, thereby shuttling it to the cytoplasm and 
relieving transcriptional repression.  However, the mechanism by which the Snf1 complex is recruited to the 
GAL1 promoter has never been examined. 
 
During Snf1 activation, the Gal83 isoform has been shown to be the complex that 
predominantly localizes to the nucleus, with the Sip2 isoform staying largely 
cytoplasmic and the Sip1 isoform maintaining a vacuolar subcellular 
localization.44  Consistent with this model, the MuDPIT data shows a nearly five-
fold increase over background for spectral counts supporting a nuclear Gal4-
Gal83 interaction when cells are grown in galactose.  Furthermore, the remaining 
two beta subunits, Sip1 and Sip2, are present in the data but not significantly 
enriched in either condition tested. As shown in Table 1, a significant number of 
spectral counts is also observed for a Gal4-Snf1 interaction, but the +UV sample 
is hardly enriched over background signal for Snf1.  The ample quantity of Snf1 
in the control non-UV sample can be explained by the reactivity of Snf1 with the 
nickel purification columns, given the presence of a poly-histidine stretch in the 
amino-terminal portion of Snf1 that binds the Ni-agarose extremely well.  Thus, 
as a result of the tandem purification method, any available form of Snf1, either 
free or crosslinked with Gal4, was purified from solution.  As such, it was critical 
to test crosslinking of Gal4 to the individual subunits of the Snf1 complex using 
Western blots and validate the hits from the MS data. 
4.D.1. Crosslinking Gal4 to myc-tagged Snf1 complex components 
In the absence of antibodies for all subunits of the Snf1 complex, 6x myc-tagged 
Snf1, Snf4, Sip1, Sip2 and Gal83 constructs were created to allow for 
immunological detection with an -myc HRP antibody.  These constructs were 
co-expressed alongside the LexA+Gal4 F849Bpa-1xflag-6His activator and the 
tRNA/RS required for Bpa incorporation.  Live yeast were then irradiated with UV 
light for 30 minutes and following cell lysis, the lysates were immunoprecipitated 
with a LexA antibody to isolate the Gal4 crosslinked products.  The resulting 
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Western blot was then probed with an -myc antibody to detect the presence of a 
covalently bound myc-tagged Snf1 complex subunit.  As expected based on 
previous localization data, no crosslinked adduct between Gal4 and Sip1, the 
subunit that is primarily localized to the vacuole in yeast, was observed.   
Additionally, no crosslinking between Snf4 and Gal4 was observed, suggesting 
that this subunit does not serve as a target during recruitment of Snf1.  However, 
as discussed in Chapter 2, further tests will have to be conducted in order to 
verify this negative result. In contrast, a clean crosslinking product for Gal83 and 
Snf1 was detected (Figure 4-5a, b), indicating a direct interaction between these 
subunits and Gal4 during transcriptional regulation.  A surprising result, Sip2 was 
also found to be a direct target of Gal4 in live yeast, contrary to localization data 
demonstrating a largely cytoplasmic residency of this protein (Figure 4-5c).  
Additionally, because Gal4 and the Snf1 complex have been demonstrated to be 
inactivated under conditions of high glucose, we hypothesized that this 
interaction should not occur in yeast grown in this sugar.  Indeed, as expected, 
crosslinking between Gal4 and the Snf1 kinase subunits is significantly 
diminished in the presence of glucose, further supporting the interdependent role 
of these proteins in regulating stress response pathways in response to changes 





Figure 4-5 In vivo photocrosslinking with Bpa captures direct targets of Gal4 within the Snf1 kinase complex.  
6xmyc tagged version of each subunit of the Snf1 kinase complex were co-expressed alongside LexA+Gal4 
F849Bpa 6HIS-flag and the tRNA/RS required for Bpa incorporation in yeast.  Yeast cells were irradiated 
with UV light and then lysed.  The covalent complexes were purified from yeast lysate through 
immunoprecipitation with a LexA antibody followed by subsequent visualization of crosslinked products via 
Western blotting with a myc antibody.  Under repressive glucose conditions, crosslinking to Snf1 subunits 
was not observed.  However, when cells were grown under glucose limiting conditions, Gal4 crosslinked 
readily to Snf1, Gal83 and Sip2. Thus in this experimental context, Gal4 makes direct contacts with three 
Snf1 subunits in live yeast.  
 
4.D.2. Snf1 homology in other eukaryotes 
The Snf1 complex is highly conserved among eukaryotes including plant and 
mammalian systems where it functions in stress-response pathways to maintain 
energy homeostasis.  The mammalian counterpart of the yeast Snf1 kinase 
complex, AMPK, plays a significant role in maintaining cellular homeostasis by 
functioning in some cases as a tumor suppressor and additionally as a regulator 
of energy response. 50,51 Given its important role in the cell, AMPK is currently 
emerging as a relevant target in the treatment of diseases that exhibit abnormal 
metabolic profiles including certain cancers as well as diabetes.52-55  Additionally, 
AMPK has been suggested to be an important regulator of activator function, 
involved in the activation of p53 mediated apoptosis under conditions of glucose 
depletion and additionally responsible for the phosphorylation of numerous 
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transcriptional targets including critical coactivators such as p300 and histone 
deacetylases as well as activators such as p53 and FOXO3. 56,57  Thus, the 
Snf1/AMPK complex likely plays an important role in transcriptional PPI networks 
and regulating expression of genes required for cell survival. 
4.D.3. Examining crosslinking of VP16 and Snf1 kinase 
Studies in yeast with the activator Gal4 indicated that recruitment of the Snf1 
complex occurs through targeting of the catalytic Snf1 subunit and through an 
additional contact with either of two regulatory subunits, Gal83 and Sip2. Given 
the high homology between yeast Snf1 and mammalian AMPK, the interactions 
of VP16, a viral activator that functions in the HSV-1 infection of mammalian cells, 
with the Snf1 complex was examined to determine if recruitment also occurs 
through targeting of the essential Snf1 subunit.  LexA+VP16N L444Bpa was 
transformed into yeast alongside the tRNA/RS required for Bpa incorporation.  
Following irradiation of live yeast, the cells were lysed and the lysates 
immunoprecipitated with a Snf1 antibody to pull out endogenous Snf1 and the 
subsequent Western blot was probed with an -Flag antibody to detect the 
presence of a covalent Snf1-VP16 complex.  As with Gal4, a direct contact 
between VP16N and Snf1 was observed, suggesting that this subunit is a 
common target among these two activators (Figure 4-6).  However, further 
experiments are required to examine if Gal4 and VP16 target overlapping 
domains on Snf1. 
 
 
Figure 4-6 VP16 directly contacts endogenous Snf1 in yeast.  Yeast expressing LexA+VP16N L444Bpa and 
the tRNA/RS required for Bpa incorporation were irradiated with UV light to activate Bpa crosslinking.  
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Following lysis, yeast lysates were immunopurified with a Snf1 antibody and subsequent Western blots were 
probed with a Flag antibody to detect the presence of a covalently bound VP16. The observation of a VP16-
Snf1 crosslinked product indicates that the Snf1 subunit is a shared target between the amphipathic 
activators Gal4 and VP16.   
 
4.D.4. Future investigations of Gal4-Snf1 kinase interactions 
 In vivo photocrosslinking combined with MuDPIT analysis revealed that 
the Snf1 kinase complex is a target of Gal4 in yeast, with further analysis 
indicating that the Snf1, Gal83 and Sip2 subunits specifically act as handles for 
recruitment of this complex in vivo.   The Snf1 complex has been suggested to 
phosphorylate transcriptional activators and additionally associate with the 
Mediator complex thus establishing its importance in transcriptional pathways.  
However, it remains unclear whether the Gal4-Snf1 complex interactions 
identified in this study occur in the context of a free or DNA-bound activator.  As 
such, investigations examining these interactions in the context of a DNA bound 
activator using tandem reversible and irreversible crosslinking (TRIC) are 
currently underway.  Furthermore, although some transcriptional activators have 
been identified as substrates of Snf1/AMPK, it is unknown whether this is also 
true for Gal4.  Snf1 is a serine/threonine kinase known to phosphorylate 
substrates containing a consensus sequence of  XRXXS/TXXX.58Interestingly, 
a portion of the Gal4 TAD contains a loose variation of this sequence 
(MFNTTTMDDV), suggesting that Gal4 may also be a substrate of the Snf1 
complex in addition to the other transcriptional complexes with which it has been 
shown to associate.  As such, the nature of the Gal4-Snf1 interaction will be 
investigated further, focusing in particular on variations in the phosphorylation 
state of Gal4 as a function of Snf1 activity.   Finally, we are poised to investigate 
additional interactions identified through MuDPIT analysis of Gal4 crosslinked 
products, including the interaction with the proteasomal component Blm10, a 
complex whose regulation of activators is believed to have a significant impact on 
activator function.   In these future experiments, it will likely be beneficial to 
104 
 
evaluate the utility of other affinity tags, such as streptavidin or GST, to avoid 
contamination problems that were observed during Ni-affinity purification of the 
6xHis tag used in these studies.   
4.E. Lessons learned from in vivo crosslinking and MuDPIT analysis 
Although the combined in vivo photocrosslinking and MuDPIT approach was 
successful in identifying several novel, direct interactions of the yeast activator 
Gal4, a significant limitation to this approach became increasingly evident with 
each batch of sample analyzed.  Specifically, the bias of mass spec based 
approaches such as MuDPIT in identifying high-abundance peptides proved to 
be a major hindrance in obtaining a well-defined interaction profile of Gal4.  For 
example, the most prominent results from these studies (i.e. the proteins with the 
highest spectral counts) included highly abundant cellular proteins such as 
molecular chaperones and ribosomal proteins.  In accordance with this bias, the 
more abundant Gal83 (3,500 copies/cell) was enriched in the MS data but Sip2 
(300 copies/cell) was overlooked, despite both being direct binding partners of 
Gal4.  This limitation has been present since the invention of MuDPIT where, of 
the 1,484 proteins observed from the yeast proteome, only 19% of the proteins 
present at <5000 copies/cell were observed, compared to a nearly 90% 
sequence coverage for proteins present at >50,000 copies/cell.22  Furthermore, 
similar to our findings, isotopic labeling does not alleviate this bias, as follow up 
studies examining changes in the abundance of 688 yeast proteins again 
demonstrated a poor sequence coverage for those present at <5000 
copies/cell.59  As such, it was not surprising that MuDPIT analysis of crosslinked 
Gal4 products failed to identify transcriptional proteins that have been identified 
as direct partners of Gal4 through previous in vivo crosslinking investigations 
including Med15 (606 copies/cell), Taf12 (930 copies/cell), and Snf2 (217 
copies/cell).  Thus, while the work in this chapter demonstrates that in vivo 
photocrosslinking and mass spec analysis was critical for the identification of the 
Snf1 kinase complex as a novel target of Gal4, the inability of this method to 
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identify low-abundance, validated targets of Gal4 indicates that significant 
advances must be made in order to use this approach to its fullest potential. 
Furthermore, it demonstrates that follow-up in vivo crosslinking experiments are 
absolutely essential to validate hits from MuDPIT analysis. 
4.F. Conclusions 
In sum, the data in this chapter represents a significant step toward the 
development of complete and accurate interaction maps of transcriptional 
activators, long an elusive goal.  A combination of in vivo photocrosslinking with 
the unnatural amino acid Bpa followed by covalent adduct analysis using the 
powerful mass spectrometric method MudPIT resulted in the identification of 
several subunits of the Snf1 kinase complex as novel, direct targets of the yeast 
activator Gal4.  Although several attempts to enhance the signal of low 
abundance peptides were made, further optimizations will be required to reduce 
the bias of MuDPIT toward the identification of higher abundance peptides and 
thus use this method to its fullest potential.  In the future, we believe this 
approach will be effective in establishing a more complete picture of the 
interactions that comprise transcriptional networks as well as other PPI systems 




Yeast Strain LS41 [JPY9::pZZ41, Mata  his3Δ200  leu2Δ1  trp1Δ63  ura3-52 
lys2Δ385  gal4 URA::pZZ41] was used for the crosslinking experiments.  Bpa 
was purchased from Chem-Impex International (Wood Dale, IL). All plasmids 
described below were constructed using standard molecular biology techniques. 
The sequences of all the isolated plasmids were verified by sequencing at the 
University of Michigan Core Facility (Ann Arbor, MI). 
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Plasmid name Function 
 
 






with a TAG 
replacing the 
codon of the 
existing amino acid 
 
pSNRtRNA-pBpaRS Expresses tRNA 
under the control 






pMyc Gal80 Expresses full 
length Gal80 fused 
to c-myc tag on N 
terminus of protein;  
pLexA+Gal4 F849Bpa 6His-Flag Expresses LexA(1-
202)+Gal4(840-
881)+6xHIS and 
1xFLAG tag  with a 
TAG replacing the 




4.G.1. In vivo cross-linking to capture the Gal4-Gal80 interaction 
To perform in vivo cross-linking, an individual colony of pLexA+Gal4 F849TAG-
6HIS-flag was grown in 10 mL SC media containing 2% Raffinose but lacking 
existing amino acid 
p6XMyc-Snf1 Expresses full 
length Snf1 fused 
to a 6x c-myc tag 
on C terminus of 
protein; 
p6XMyc-Gal83 Expresses full 
length Gal83 fused 
to a 6x c-myc tag 
on C terminus of 
protein; 
p6XMyc-Sip2 Expresses full 
length Sip2 fused 
to a 6x c-myc tag 





length Snf4 fused 
to a 6x c-myc tag 





length Sip1 fused 
to a 6x c-myc tag 




histidine and tryptophan for selection. The cultures were incubated overnight at 
30 °C with agitation. Following incubation, these cultures were used to inoculate 
1L cultures of SC media containing 2% Glucose. Control samples were grown in 
2% Raffinose and 2% Galactose.  For pBpa incorporation, 10 mL 100 mM pBpa 
dissolved in 1M NaOH and 10 mL 1M HCl were added to the above cultures. The 
cultures were incubated overnight at 30 °C with agitation to an OD660 of ~0.8. 
When cultures reached the appropriate OD660, the cells were spun down by 
centrifuging at 6000 rcf at 4oC for 15min. following which the cell pellets were 
washed with SC media lacking histidine and tryptophan.  The cell pellets were 
resuspended in 2mL SC media lacking histidine and tryptophan + either 2% 
Raffinose and 2% Galactose or 2% Glucose and transferred to cell culture dishes 
and subjected to UV irradiation at 365 nm light (Eurosolar 15 W UV lamp) with 
cooling for 0.5 h. The cells were isolated by centrifugation and stored at -80oC 
until lysis.  
 
Cryolysis procedure 
Cryolysis was performed using the Retsch planetary ball mill PM 200 in the 
Skiniotis Lab (LSI, University of Michigan).  Chambers and balls were submerged 
in liquid nitrogen to cool equipment down.  Frozen yeast cells were crushed in a 
chilled mortar and pestle (chilled in liquid nitrogen) and were then added to the 
chilled chambers. 3 balls/chamber were then added and then the lid was 
clamped in place. Liquid nitrogen was ladled over the closed chambers 
repeatedly to keep cells and equipment chilled.   Balanced chambers were 
loaded into the cryomill machine and clamped into the machine.  Machine was 
run for two minutes at 500 r.p.m.  When done, the chambers were removed and 
again chilled with liquid nitrogen and then run for another cycle in the PM200 
machine.  This procedure was repeated for a total of 3 cycles.  Chambers were 
removed from machine after final spin and the frozen lysed yeast were recovered 





Lysed yeast were allowed to thaw in a cold water bath and then centrifuged for 
30 minutes at 4 deg C, 9299 rcf (Beckman Coulter Allegra X-22R, fixed rotor).  
While cells were spinning, 300-500 L Ni-agarose bead slurry was washed three 
times with 1 mL chilled PBS.  After centrifugation is complete, supernatant from 
lysed yeast is transferred to a clean 50 mL Falcon tube and the Ni-agarose 
beads (resuspended in 1 mL chilled PBS) are added to the supernatant.  Beads 
and supernatant are incubated for 1 hour on rotating carousel in 4 deg C cold 
room.  After incubation, beads are spun down (low rpm) and the supernatant is 
pipetted off.  The Ni-agarose is resuspended in the remaining supernatant, 5 mL 
chilled Nickel Wash Buffer (100 mM PBS pH 7.0, 150 mM NaCl, 10% glycerol, 
0.5% NP-40 + 2 protease inhibitor tablets (Roche Complete minis, EDTA free) 
and 10 mM betamercaptoethanol) was added to beads and then transferred to a 
15 mL falcon tube.  Beads in buffer were centrifuged at 2500 rpm, 2 minutes, 4 
deg C (Beckman Coulter Allegra X-22R, bucket rotor) and the supernatant 
decantant.  This procedure was repeated 4 more times for a total of five 5mL 
washes.  The beads were then washed twice with 5 mL cold 100 mM PBS.  PBS 
was decanted and the beads were resuspended in ~500 L 100 mM PBS and 
transferred to a chilled 1.75 Eppendorf flip cap tube.  Residual beads on the 15 
mL tube were washed with about 500 L 100 mM PBS and transferred to 
Eppendorf tube.  Beads were spun briefly at low rpm (Eppendorf 5417C 
microfuge).  The PBS was pipetted off and discarded.  
Beads were resuspended in 500 L chilled Nickel Elution Buffer (100 mM PBS, 
pH 7.0, 500 mM Imidazole, 0.5% Tween-20) and mixed gently for 1 minute by 
inversion and then recentrifuged.  The supernatant (eluant) was pipetted off and 
collected in a separate, clean 1.75 mL Eppendorf tube.  Another 500 L chilled 
Nickel Elution Buffer was added to the beads and mixed by inversion for 10 
minutes, 4 deg C in a cold room.  During the second elution, a 10K concentrator 
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was washed with 100 mM PBS.  The first elution was centrifuged to remove any 
lingering Ni-agarose and the eluant was pipetted out and added to the 
concentrator.  Concentrator was spun at 15,000xG for 5 minutes at 4 deg C.  
Elutions were repeated for a total of 3 elutions, each elution added to the 
concentrator after centrifugation to remove residual Ni-agarose.  After 
concentrating the three elutions, the volume should be close to 100 L.  500 L 
of 100 mM chilled PBS was added to the protein and then run through the 
concentrator.  This was repeated for a total of 3 PBS buffer exchanges to get a 
final volume of 100-150 L of protein. 
400 L of Flag-agarose was washed three times with 1 mL Flag Wash Buffer 
(100 mM PBS, 150 mM NaCl, 0.5% NP-40).  Concentrated sample was added to 
the Flag-agarose (Sigma, M2).  The concentrator was washed with a small 
volume of 100 mM PBS and added to the Flag-agarose incubation (2 hours, 4 
deg C, with rotation on carousel).  Flag-agarose was then washed ten times with 
1 mL/wash Flag Wash Buffer, spinning between washes (5000 rpm, 30 sec, 
Eppendorf 5417C).  Agarose was washed twice with 100 mM PBS to dilute out 
the NP-40.  1 mL of Flag Elution Buffer (100 mL PBS, pH 7.0, 0.1% NP-40, 350 
mM NaCl) containing 10 mg/mL flag peptide was thawed from -80 deg C.  333 L 
Flag elution buffer was added to washed Flag-agarose and incubated for 30 
minutes, 4 deg C, with rotation.   Beads were briefly centrifuged and the elution 
transferred to a new 1.75 mL Eppendorf tube.  Elution was quick frozen in liquid 
nitrogen and stored in -80 deg C freezer.  Second elution was performed in the 
same fashion and the final 333 L was added to beads for a third elution that was 
allowed to run overnight.  The next morning, the two frozen elutions were thawed 
and spun down to remove residual Flag-agarose.  Elutions were transferred to 
new tubes and then centrifuged again to remove any chance of residual beads 
remaining.  These first two elutions, cleared of all beads, were then concentrated 
in a 10K concentrator at 15,000 xG until down to 100 L.  The overnight elution is 
then added and centrifuged down to 100 L.  500 L of Ammonium bicarbonate 
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(50 mM) was then added to the concentrator for a total of 4 buffer exchange 
cycles with the protein.  Concentrated sample was then transferred to a clean 
Eppendorf tube.  Concentrator was washed with a little ammonium bicarbonate 
and then added to the sample.  Sample was quick frozen in liquid nitrogen, 
packed in dry ice, and shipped to the Cravatt Lab overnight.    
4.G.2. MuDPIT analysis 
All MuDPIT analyses were performed by Dr. Sherry Niessen at the Center for 
Physiological Proteomics in La Jolla, California.  Crosslinked products were 
denatured by resuspending in an equal volume of 8M urea, 50 mM Tris (pH 8.0). 
10-20 mg of protein was then reduced with 10 mM Tris(2-carboxyethyl) 
phosphine HCl (TCEP, Sigma) for 30 minutes at room temperature.  The proteins 
were then alkylated with fresh 12.5 M iodoacetamide (IAA; Sigma) and the 
concentration of urea was reduced to 2 M by adding 50 mM Tris (pH 8.0).  
Crosslinked proteins were then digested overnight with 1 mM CaCl2 and 0.2 mg 
Trypsin and incubated at 38 deg C.  Digested peptides were then acidified in 5% 
formic acid and centrifuged at 17,000 xg for 15 minutes.  Half of the digested 
mixture was pressure loaded onto a biphasic strong cation exchange/reverse 
phase capillary column and separated by 2D liquid chromatography and tandem 
MS using an 11 step gradient on an LTQ-Orbitrap LX hybrid mass spectrometer.  
MS spectra were acquired in centroid mode, with a mass range of 400-1,800 in 
the Orbitrap analyzer with resolution set at 30,000 followed by 7 MS/MS scans in 
the ion trap.  All MS/MS spectra were collected using a normalized collision 
energy of 35% and an isolation window of 2 Da. One microscan was applied for 
all experiments in the Orbitrap or LTQ.  Spray voltage was set to 2.50 kV, and 
the flow rate through the column was 0.20 uL/min. 
4.G.3. Crosslinking with myc-Snf1 subunits.   
For crosslinking studies with mycSnf1 subunits, the procedure was identical 
except that cells were scaled down to 100 mL cultures in SC media lacking 
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histidine, leucine, and tryptophan.  For lysis, cells were resuspended in 600 μL 
Lysis buffer (50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton 
X-100, 0.1% Na-Deoxycholate and 2X Complete Mini, EDTA Free Protease 
Inhibitor (Roche) and lysed using glass beads by vortexing at 4 °C. Subsequently, 
the lysate was pelleted and the supernatant incubated with 10 μL of LexA 
antibody (sc-1725, Santa Cruz Biotechnologies) (or in the case of VP16-Snf1, 
lysates were immunoprecipitated with a Snf1 antibody – Santa Cruz, sc-15621) 
for 2 h at 4 °C for immunoprecipitation. The protein bound to the antibody was 
isolated by incubation for 1 h with either ~50 μL of prewashed protein G magnetic 
beads (Dynal Corporation, Invitrogen, Carlsbad, CA) or ~ 8 uL prewashed protein 
G agarose beads (Millipore) at 4 oC. After immunoprecipitation, the beads were 
washed 6 times with 1 mL Wash Buffer (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 
0.5% NP-40, 0.1% Na-Deoxycholate and 1 mM EDTA) and stored dry at -80 oC 
until elution. The crosslinked sample was eluted from the beads by heating at 95 
oC for 10 min in NuPAGE 4x LDS Sample buffer (Invitrogen, Carlsbad, CA) 
containing 250 mM DTT and probed using Western Blot analysis using anti-
FLAG (M2) antibody (Sigma, St. Louis, MO) or anti-myc antibody (SC-40 HRP, 
Santa Cruz Biotechnology, Santa Cruz, CA). 
4.G.4. β.Galactosidase assays 
To evaluate the ability of each LexA+Gal4 F849Bpa-6HIS-flag to activate 
transcription in the presence or absence of glucose, saturated cultures (SC 
media + 2% Raffinose ) of each mutant were used to inoculate 5 mL SC media 
containing either 2%Glucose or 2% Raffinose & 2% Galactose but lacking 
histidine and tryptophan for selection. The cells were grown to an OD of 0.8-1 
and harvested. The activity of each construct was monitored using β-
galactosidase assays as previously described.60 
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Chapter 5 Conclusions and Future Directions 
 
5.A. Introduction 
Protein-protein interaction (PPI) networks govern nearly every essential 
regulatory process in the cell including protein synthesis and folding, cell 
signaling, and transcriptional regulation.  These networks are complex, 
comprised of thousands of contacts that vary in affinities, interaction area, and 
lifetimes.  Of particular importance to biological systems are networks that 
heavily utilize transient PPIs of moderate to low affinity, as these are essential to 
the proper function of regulatory cellular processes.  Transient interactions often 
enable a protein to engage in multiple contacts, and this can occur through re-
use of the same interface. Aberrations within PPI networks are a hallmark of 
various disease states; therefore, there is great interest in designing compounds 
to target PPIs in order to learn more about how they function and, in the long 
term, restore normal cell phenotype.  However, this effort has been hindered by a 
lack of structural and mechanistic data, particularly with regards to transient PPIs 
that have historically been the most challenging to study.  
 The challenges associated with studying transient PPI networks are particularly 
apparent in the process of transcriptional initiation. At the heart of this process 
are transcriptional activators, a family of signal responsive proteins that localize 
to gene promoters and use a single transcriptional activation domain (TAD) to 
recruit numerous multi-protein coactivator complexes required for up regulation 
of gene expression.  Activators are dynamically engaged with the transcriptional 
machinery through a coordinated series of contacts that range greatly in affinities 
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and interaction areas.  Although co-localization studies have identified the 
complexes that are recruited by activators during transcription, the direct targets 
within these complexes in cells remains largely unknown.  Furthermore, due to 
the limitations of methods such as co-immunoprecipitation in detecting transient, 
lower affinity interactions, many binding partners of activators may remain 
unidentified. As a result, the interaction map for transcriptional PPI networks is 
currently incomplete and is lacking critical information necessary to aid the 
rational design of small molecules to transiently perturb this system reveal key 
insights into how it functions. 
 As demonstrated in this dissertation, in vivo photocrosslinking with a 
genetically incorporated photo-labile amino acid is a powerful approach to 
capture the direct binding partners of transcriptional activators in living cells. This 
includes transient, moderate affinity interactions that are typically challenging to 
study.  Furthermore, the use of a combination of in vivo chemical capture and 
mass spectrometry revealed several novel binding partners of a yeast activator, 
indicating the power of this combined approach in building a more complete 
interaction map for transcriptional PPI networks.  Finally, a novel method was 
developed to examine the direct interactions of DNA bound transcriptional 
activators in vivo, thus affording the ability to examine the most functionally 
relevant interactions in a cellular context. In all, the work performed in this 
dissertation not only contributes to advancing the longstanding goal of creating 
complete interaction maps for activators, but it also indicates that these 
approaches can be used more broadly in the examination of other regulatory PPI 
networks that rely on transient interactions to function. 
5.B. In vivo photocrosslinking is a powerful method for the capture of a broad 
range of activator PPIs in yeast 
A key finding from this work is that covalent chemical capture using genetically 
encoded p-benzoyl-l-phenylalanine (Bpa) is a powerful tool to capture the direct, 
cellular binding partners of transcriptional activators. The utility of this 
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methodology is demonstrated in Chapter 2 by the in vivo covalent chemical 
capture of the moderate affinity interaction between VP16 and Med15 (KD~ 0.1-
10 M) as well as capture of a higher affinity contact with TBP (KD~33 nM), an 
interaction whose occurrence in cells has been contested prior to this study.1-3  
Furthermore, capture of the direct targets of VP16 within the low abundance 
Swi/Snf complex demonstrates the power of this approach in studying 
transcriptional PPI networks whose constituent interactions are often mediated 
by low-abundance proteins. The data in Chapters 2 and 3 also demonstrate that 
a negative result must be interpreted cautiously, as the lack of a crosslinking 
product could arise from a variety of factors including poor positioning of the 
crosslinking amino acid or an inherent reactivity that is poorly suited for a given 
PPI interface.  Furthermore, the use of a detection system that lacks the 
sensitivity to observe a crosslinked product may be a significant problem when 
examining very small quantities of crosslinked proteins.4,5  Finally, when 
combined with mass spectrometric based methods designed to identify complex 
protein mixtures, in vivo photocrosslinking is tremendously useful in identifying 
the novel targets of transcriptional activators, as demonstrated in Chapter 4 by 
the discovery of Snf1, Gal83, and Sip2 as direct targets of the transcriptional 
activator Gal4.  
5.C.Recruitment of multi-protein complexes involves the targeting of multiple 
subunits 
At the core of transcriptional PPI networks are multi-protein complexes that are 
composed of at least one enzymatic subunit, several scaffolding proteins, and 
any number of regulatory subunits that associate either stably or transiently with 
the complex to modulate complex function and localization. The experiments of 
Chapter 2 examined the recruitment of the Swi/Snf chromatin remodeling 
complex whose core enzymatic subunit, the Snf2 ATPase, associates with at 
least 9-11 other proteins in the cell.  In vivo photocrosslinking with VP16 showed 
that recruitment of this complex occurs through a direct interaction with the 
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enzymatic Snf2 subunit and additional targeting of Snf5 and Snf6, three proteins 
that have been shown to be functionally interdependent.6 Furthermore, in 
mammalian systems, INI1/Snf5 has been demonstrated to enhance the activity of 
BRG1/BRM (Snf2), thus indicating the role of this subunit in modulating complex 
function.7  In Chapter 4, we examined the interactions of Gal4 with the Snf1 
kinase complex and found that Gal4 targets the catalytic subunit Snf1 in addition 
to two regulatory proteins, Gal83 and Sip2, that associate transiently with the 
complex to fine tune subcellular localization.8 Thus, it appears that activators 
target multiple subunits of coactivator complexes and furthermore that the 
enzymatic subunit is often, but not always, a shared target of amphipathic 
activators.  As such, the results of the studies in this thesis support a model 
wherein activators target the minimal functional component of the complex while 
additionally targeting associated factors, perhaps as a means to recruit specific 
complex isoforms whose subunit association confers differential activity profiles.   
5.D. Future Directions 
5.D.1. Moving into an endogenous system 
The work outlined in this thesis contributed several novel findings including in 
Chapter 2 the first demonstration of the utility of in vivo photocrosslinking in 
capturing a transient, moderate-affinity interaction.  In Chapter 3, the use of TRIC 
to examine the VP16-TBP interaction was the first demonstration of the capture 
and visualization of the direct interactions of DNA bound activators.  And finally, 
the work in Chapter 4 was the first study of its kind in using in vivo 
photocrosslinking combined with MuDPIT to identify novel interaction partners of 
the activator Gal4.   
While the studies with model systems in this thesis (i.e. LexA-VP16 in yeast) 
yielded a significant amount of data, the long-term goal is to examine activator 
function in a context that more closely resembles its natural state.  Specifically, 
the future goal would be to site specifically introduce an amber stop codon into 
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the endogenous gene, for example Gal4, so that Bpa containing activator is 
expressed at levels more comparable to that found in nature.  However, due to 
relatively poor incorporation rates of Bpa in activators expressed from plasmids 
(about 20%), significant optimization in Bpa mutant expression will be required 
before this can be achieved.  If this can be achieved, however, it will represent a 
significant step toward understanding how natural activators function to 
upregulate transcription across the genome.  
Thinking more broadly in the context of entire transcriptional PPI networks, this 
technology can also be employed to examine the inter- and intra-molecular 
interactions of other transcriptionally relevant complexes.  For example, 
combinatorial complex assembly is a popular strategy employed in transcriptional 
systems to control complex localization and function.  Perhaps in vivo 
photocrosslinking can be used to investigate the identity and positioning of 
exchangeable subunits within these complexes and, furthermore, identify 
changes in the interactions with other complexes that come as a result of this 
exchange.  Different isoforms of the Pol II holoenzyme, general transcription 
factor complexes, and chromatin modifying complexes, for example, have all 
been reported; however, the contact fluctuations within the PPI network that 
come as a result of these differentially composed complexes remains to be seen.  
To address this, a combined approach such as that used in Chapter 4 would be 
useful given the ability of proteomics approaches to examine a spectrum of 
interactions in a relatively unbiased manner.  
 Furthermore, one could easily imagine the utility of the in vivo crosslinking 
strategy in examining the PPIs that govern not just transcriptional initiation, but 
also events surrounding elongation and termination.  For example, the 
interactions that RNA polymerase II makes with elongation and termination 
factors and the interactions of transcriptional complexes with the nuclear pore 
complex could all be examined using Bpa crosslinking.  Furthermore, the 
changes in interactions of Pol II on DNA could theoretically be examined using 
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TRIC.  In particular, by decreasing the crosslinking time of the formaldehyde 
using rapid mixing techniques, work in this area may be able to reveal a detailed 
portrait of the PPIs regulating Pol II function over the entire course of 
transcription.  Not only would this be of great benefit to the field, but it has the 
potential to identify PPIs that could be selectively targeted to activate or inhibit 
transcription at each identifiable stage. 
5.D.2. Incorporation of other unnatural amino acids to examine the mechanism of 
activator recruitment 
Although the work in this thesis primarily focused on the use of Bpa to capture 
activator-coactivator interactions in vivo, the incorporation of other amino acids 
could provide complementary information to these studies.  For example, p-
azido-phenylalanine not only provides a crosslinking moiety for complementary in 
vivo crosslinking studies, but the azide functional group also provides a handle 
with which new functionalities can be added through the use of Click chemistry or 
a Staudinger ligation.  In theory, an Azpa containing activator could be labeled 
with an alkynl-fluorophore, either through copper catalyzed reaction in cell 
lysates or through a strain-promoted reaction that removes the requirement of 
toxic copper.  In this way, the labeling of proteins in living cells would allow for 
the visualization of protein movement and complex dynamics, adding yet another 






















In light of issues detailed in Chapter 4 surrounding purification strategies, a 
particularly attractive strategy is to incorporate Bpa derivatives that possess an 
alkynyl handle, thus removing the need for exogenous tags such as the 6xHis tag 
used in our earlier purification strategy.  This not only provides another handle for 
purification, but as the alkyne is not naturally available, it will be specific to the 
protein in which it is incorporated.  Thus, the Bpa-alkyne derivatives should react 
bioorthogonally with a biotin-azide handle, for example, and eliminate cross 
reactivity issues associated with the use of Ni-agarose purification strategies. 
Preliminary work done with Cassandra Joiner and Dr. James Clayton 
demonstrates that Bpa containing an installed alkyne handle (Bpyne), is able to 
be incorporated into Gal4 in yeast and, furthermore, that this modification does 
Figure 5-1 Schematic of fluorophore conjugation to proteins labeled with Azpa.  Azpa 
containing proteins are expressed in cells that have taken up a fluorophore with a bio-orthogonal 
reactive handle.  This leads to fluorescent labeling of the protein in cells and allows protein 
localization and dynamics to be monitored.  Alternatively, fluorescent unnatural amino acids can be 
directly incorporated into proteins provided the tRNA/RS have been engineered for this function. 
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not impair crosslinking ability (Figure 5-2).  In the future, we foresee Bpyne being 
tremendously useful in crosslinking experiments, as following cell lysis, we 
should be able to click on a biotin-azide purification handle to pull out covalent 
activator complexes, thus removing the need for antibodies that can be costly 
and ineffective.  
Bpa-alkyne derivatives and p-Azido-phenylalanine can also be useful in 
conjugating fluorophores to proteins for in situ or in vivo visualization studies.  
Because both of these amino acids can currently be incorporated into proteins in 
yeast, one could reasonably begin labeling these proteins using click chemistry 
to covalently attach a fluorescein or Cy5 fluorophore.  Labeled proteins could 
then be visualized using a number of available microscopy techniques.  For 
example, the shuttling of transcriptional complexes into and out of the nucleus 
could be observed via this route, adding complementary data to what may be 
observed in TRIC studies.  Future work in this area may also focus on the direct 
incorporation of fluorophores using the nonsense suppression strategy.  However, 
in order for this to be realized, a tRNA/RS pair would have to be selectively 
evolved to incorporate the fluorescent amino acid.   While this appears more 
plausible for smaller fluorescent groups such as coumarin, the quantum yield of 
such fluorophores is unfortunately often too low to overcome background 
fluorescence in cells.   Fluorophores like Cy3, Cy5, fluorescein and the Alexa 
series are far better for in situ visualization, but are much larger in size and may 
be more difficult to fit into the active site of a tRNA synthethetase, even after 
extensive engineering.  Regardless, labeling of proteins for visualization studies 




Figure 5-2 A. Several Bpa derivatives are being pursued in the Mapp group, each with an orthogonally 
reactive handle including terminal alkynes, azides, and ketones.  B. One amino acid, Bpyne/Epyne, has 
already been incorporated into Gal4 in our lab and with yields comparable to Bpa.  D. When tested for 
crosslinking potential, bot Bpa and Bpyne displayed a similar crosslinking profile.  C. Examples of how high 
efficiency purification handles can be conjugated to Bpa derivatives.  Work in these figures executed by Dr. 
James Clayton and Cassandra Joiner.  
In sum, the future of unnatural amino acids in the study of PPI networks is 
promising.  In this dissertation, two amino acids in particular, p-benzoyl-L-
phenylalanine (Bpa) and p-azidophenylalanine (Azpa) were used to covalently 
capture the direct interactions of transcriptional activators in live yeast.  Moving 
forward, studies with these amino acids and others with new chemistries can be 
applied to other PPI networks whose constituent interactions have proven 
challenging to study. 
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